 
RAZIEL THERAPEUTICS  LTD . 
 
INVESTIGATIONAL NEW DRUG PROTOCOL  
 
RZL -012 
PROTOCOL NUMBER RZL -012-FL-P2US-001 
VERSION 1.1 
30 MAY 2022  
 
A DOUBLE -BLIND PLACEBO -CONTROLLED PHASE 2 STUDY TO EVALUATE 
THE SAFETY AND EFFICACY OF RZL -012 TREATMENT IN SUBJECTS SEEKING 
FAT REDUCTION IN THE FLANKS  
SPONSOR:  
Raziel Therapeutics, Ltd. 
[ADDRESS_484099] and/or Regulatory Authority under the condition that 
confidentiality is maintained.  
 
Version 1.0 :  22 November  2021  
Version 1.1: 30 May 2022  
        
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 2 of 72 CONFIDENTIAL  
 KEY CONTACTS FOR THE STUDY  
SPONSOR’S  
REPRESENTATIVES:   
Sponsor Contact  [CONTACT_24617] E. Lowenthal, M Sc, MBA  
Program Manager  
Pacific -Link Research Inc.  
Cell: +1 -[PHONE_378]  
Tel: +1 -[PHONE_379]  
E-mail: richard @pacificlinkconsulting.com  
 
Study Director  Racheli Gueta , PhD  
Raziel Therapeutics  
Director, Clinical Development  
Cell:  + 972-50-7837597  
E-mail: racheli@raziel -therapy .com  
 
Study Medical Monitor  Patricia Walker MD, PhD , MD, PhD  
Chief Medical Officer ,  
Raziel Therapeutics  
Cell: +1 -[PHONE_8045]  
E-mail: [EMAIL_2239]  
 
Serious Adverse Event Reporting  
 
 
 
 
 
  Fax:+ [PHONE_384]  
Email: 
Raziel [EMAIL_7467]  
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484100] OF APPENDICES  ................................ ................................ ................................ .................  7 
STATEMENT OF COMPLIANCE  ................................ ................................ ..............................  10 
INVESTIGATOR STATEMENT  ................................ ................................ ................................  11 
PROTOCOL SYNOPSIS  ................................ ................................ ................................ .............  13 
1.0 INTRODUCTION  ................................ ................................ ................................ .............  19 
1.1. BACKGROUND  ................................ ................................ ................................ ...............  19 
1.1.1.  Scientific Background and Clinical Rationale  ................................ ................................ . 19 
1.1.2.  RZL -012 Formulation Development  ................................ ................................ ...............  20 
1.2. NONCLINICAL ASSESSMENTS  ................................ ................................ ...................  20 
1.2.2.  Toxicology  ................................ ................................ ................................ .......................  22 
1.2.3.  Clinical Studies  ................................ ................................ ................................ ................  24 
2.0 STUDY OBJECTIVES  ................................ ................................ ................................ ...... 42 
2.1 Study Objectives  ................................ ................................ ................................ ................  42 
2.1.1  Primary Objective  ................................ ................................ ................................ ..............  42 
2.1.2  Secondary Objective  ................................ ................................ ................................ ..........  42 
2.2 Description of Study Design  ................................ ................................ ..............................  42 
2.3 Study Endpoints  ................................ ................................ ................................ .................  43 
2.3.1  Primary Endpoint  ................................ ................................ ................................ ...............  43 
2.3.2  Seco ndary Endpoints  ................................ ................................ ................................ .........  43 
2.3.3  Randomization/Assignment to Study Drug  ................................ ................................ ....... [ADDRESS_484101]  and Dosing  ................................ ................................ ................................ .... 44 
2.4.2  Dose Rationale  ................................ ................................ ................................ ...................  45 
2.4.3  Serious Adverse Events Considered Related to the Investigational Drug  .........................  45 
2.5 Concomitant Medications  ................................ ................................ ................................ .. 46 
2.5.1  Prior and Concomitant Medications  ................................ ................................ ..................  46 
3.0 STUDY POPULATION  ................................ ................................ ................................ .... 46 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484102] Identification  ................................ ................................ ................................ .........  48 
3.4 Removal, Replacement or Early Withdrawal of Subjects from the Assessment Not Due to 
Intolerable Side Effects  ................................ ................................ ................................ .................  48 
4.0 STUDY PROCEDURES AND ASSESSMENTS  ................................ .............................  48 
4.1 Informed Consent ................................ ................................ ................................ ...............  48 
4.2 Complete Physical Examination  ................................ ................................ ........................  49 
4.3 Medical History  ................................ ................................ ................................ .................  49 
4.4 Vital Signs  ................................ ................................ ................................ ..........................  49 
4.5 ECG ................................ ................................ ................................ ................................ .... 49 
4.6 Height and Weight  ................................ ................................ ................................ .............  49 
4.7 Pharmacokinetics  ................................ ................................ ................................ ...............  50 
4.8 Clinical  Laboratory Evaluations – Hematology and Serum Chemistry .............................  50 
4.8.1  Hematology  ................................ ................................ ................................ ........................  50 
4.8.2  Serum Chemistry  ................................ ................................ ................................ ...............  50 
4.8.3  Pregna ncy Tests  ................................ ................................ ................................ .................  51 
4.9 2-D and 3 -D Standardized Photography  ................................ ................................ ............  51 
4.10  Physician Global Assessment Improvement Scale (GAIS)  ................................ ..........  [ADDRESS_484103]’s Satisfaction Questionnaire  ................................ ................................ .................  52 
4.12  Evaluation of Response ................................ ................................ ................................ .... 52 
4.13  Compliance Monitoring ................................ ................................ ................................ ... 52 
5.0 SAFETY ASSESSMENTS  ................................ ................................ ................................  52 
5.1 Collection of Adverse Events Data  ................................ ................................ ....................  52 
5.2 Complete or Targeted Physical Examination  ................................ ................................ .... 53 
5.3 Vital Signs  ................................ ................................ ................................ ..........................  53 
6.0 PHARMACOKINETICS  ................................ ................................ ................................ ... 53 
7.0 EFFICACY  ................................ ................................ ................................ ........................  53 
8.0 STUDY VISITS AND  PROCEDURES  ................................ ................................ ............  53 
8.1 Screening (Days -28 to -1) ................................ ................................ ................................ . 53 
8.2 Baseline Evaluations (Day 0)  ................................ ................................ .............................  54 
8.3 Study Randomization  ................................ ................................ ................................ .........  55 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 5 of 72 CONFIDENTIAL  
 8.4 Pre-dose Evaluation (Day 0)  ................................ ................................ ..............................  [ADDRESS_484104]-dose Evaluations (Day 0) and PK blood samples  ................................ ......................  56 
8.7 Study Visits (Day 1, Week 1, 4, 8, and 12)  ................................ ................................ ....... 57 
8.8 Final Visit (Week 12)  ................................ ................................ ................................ ....... 58 
8.9 Open -Label Phase of the Study:  ................................ ................................ .....................  [ADDRESS_484105] SPECIFICATIONS  ................................ ................................ ........................  59 
10.1  Description  ................................ ................................ ................................ .........................  59 
10.2  Formulation, Packaging, and Labeling  ................................ ................................ ..............  59 
10.3  Receipt, Storage and Stability of RZL -012................................ ................................ ........  60 
10.4  Study Drug Administration  ................................ ................................ ............................  60 
10.5  Ordering and Distribution of Study Drug  ................................ ................................ ..........  60 
10.6  Accountability of Study Drugs  ................................ ................................ ..........................  60 
11.0  SAFETY MONITORING AND ADVERSE EVENTS  ................................ ....................  61 
11.1  Adverse Events  ................................ ................................ ................................ ..................  61 
11.2  Serious Adverse Events  ................................ ................................ ................................ ..... 63 
11.2.1  Reporting Requirements for Serious Adverse Events  ................................ .......................  63 
11.2.2  Reporting pregnancy  ................................ ................................ ................................ ..........  64 
11.2.3  Recording of Serious Adverse Events  ................................ ................................ ...............  64 
12.0  STATISTICAL CONSIDERATIONS ................................ ................................ ...............  64 
12.1  Sample Size Determination ................................ ................................ ................................  64 
12.2  Analysis Data Sets  ................................ ................................ ................................ .............  64 
12.3  Endpoints Analyses  ................................ ................................ ................................ ............  65 
12.4  Safety  ................................ ................................ ................................ ................................ . 65 
12.5  Efficacy  ................................ ................................ ................................ ..............................  65 
13.0  DATA COLLECTION, STUDY MONITORING, AND DATA DISCLOSURE  ............  66 
13.1  Data Collection and Reporting ................................ ................................ ...........................  66 
13.2  Study Monitoring  ................................ ................................ ................................ ...............  66 
13.3  Audit and Inspection  ................................ ................................ ................................ ..........  67 
13.4  Deviation from Clinical Trial Protocol  ................................ ................................ ..............  67 
13.5  Retention of Records ................................ ................................ ................................ ..........  67 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484106]/Ethics Committee  ................................ ................................ .. [ADDRESS_484107] Health Injury and Insurance  ................................ ................................ ..................  69 
14.5  Completion of the Study  ................................ ................................ ................................ .... 69 
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484108] OF TABLES  
Table 1  Composition of RZL -012 ................................ ................................ ...........................  20 
Table 2  Overview of Ongoing and Completed Cl inical Studies  ................................ .............  25 
Table 3  Dosages According to Lipomas Size  ................................ ................................ ..........  37 
Table 4  Dosing Regimen  ................................ ................................ ................................ .........  44 
Table 5  Severity Assessment Terminology for Reporting Adverse Events (CTCAE v 5.0)  .. [ADDRESS_484109] OF FIGURES  
Figure 1:  Structural Formula of RZL -012 ................................ ................................ ...................  20 
Figure 2:  Injection Sites for Phase 0 Study  ................................ ................................ ..................  30 
Figure 3:  Injection Sites for Phase 2A Study  ................................ ................................ ...............  31 
Figure 4:  Injections Diagram According to Lipomas Size  ................................ ..........................  33 
Figure 5:  Injection Scheme Lipedema Subjects ................................ ................................ ...........  34 
Figure 6:  Diagram of Injection Pattern  ................................ ................................ ........................  [ADDRESS_484110] OF APPENDICES  
Appendix A:  Schedule of Study Procedures  ................................ ................................ ............  70 
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484111]  Aspartate aminotransferase  
BMI  Body mass index  
BUN  Blood urea nitrogen  
CBC  Complete blood count  
cGMP  Current Good Manufacturing Practices  
CI Confidence interval  
cm Centimeter  
CNS  Central nervous system  
CRF  Case report form  
CV Coefficient of variable  
DD Dercum’s disease  
ECG  Electrocardiograms  
FDA  Food and Drug Administration  
FSH Follicle -Stimulating Hormone  
GAIS  Global Aesthetics Improvement Scale  
GLP  Good Laboratory Practice  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH-GCP  International Conference on Harmonization  Good Clinical Practice  
IND Investigational New Drug  
INR International normalized ratio  
IRB/EC  Institutional Review Board/Ethics Committee  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484112] operating procedure  
TEAE  Treatment emergent adverse event(s)  
US/[LOCATION_003]  [LOCATION_002] of America  
WBC  White blood cell  
WHODD  World Health Organization Drug Dictionary  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 10 of 72 CONFIDENTIAL  
 STATEMENT OF COMPLIANCE  
This clinical trial will be conducted in compliance with the protocol, International Conference on 
Harmonization Good Clinical Practice E6 and the applicable regulatory requirements.  
  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484113] read and understand the protocol and agree to implement the study in accordance with the 
procedures set forth in the protocol and in accordance with the Sponsor's guidelines, all 
applicable government regulations, and the International Conference on  Harmonization  Good 
Clinical Practice Guidelines E6 (ICH -GCP).  
I will maintain accurate source documents from which data are transcribed onto case report 
forms and accurate drug accountability records that show the receipt and disposition of all study 
drugs. 
I will provide adequate protocol training to my associates, colleagues, and employees assisting in 
the conduct of the study.  
I will obtain Institutional Review Board/Ethics Committee (IRB/EC) approval of the protocol 
and Informed Consent Form  (ICF)  prior to enrollment of subjects in the study. I understand that 
any modifications to the protocol made during the course of the study must first be approved by 
[CONTACT_1201]/EC prior to implementation except when such modification is made to remove an 
immediate haza rd to the subject.  
I will ensure that a fully executed IRB -approved Informed Consent Form is obtained from each 
subject prior to initiation of any study procedures.  
I will report (within 24 hours) any serious adverse event, regardless of relationship to st udy drug, 
or pregnancy that occurs during the course of the study, in accordance with the procedures 
described in Section 11.[ADDRESS_484114] was receiving this study drug.  
I will submit all protocol inclusion/exclusion violations to the Medical Monitor for approval 
prior to enrollment of the subject in the study.  
I will allow the Sponsor, Raziel Therapeutics Ltd.  (Raziel) and its agents, as well as the United 
States (U.S.) Food and Drug Administration (FDA) and other regulatory agencies to inspect 
study facilities and pertinent records at reasonable times and in a reasonable manner, ensuring 
subject confidentiality. If I am notified that this study is to be inspected by a regulatory agency, I 
will notify the Sponsor as soon as possible thereafter (no later than one  week).  
This protocol cont ains information that is proprietary to Raziel .  The information contained 
herein is provided for the purpose of conducting a clinical trial for Raziel . 
The contents of this protocol may be disclosed to study personnel under your supervision and to 
your IR B/EC. The contents of this protocol may not be disclosed to any other parties (unless 
such disclosure is required by [CONTACT_24619]) without the prior written approval 
of Raziel.  
 
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 12 of 72 CONFIDENTIAL  
 __________________ ____     _______________________ _______       ________________  
Investigator’s Name                [CONTACT_10670]’s Signature    [CONTACT_113409], Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 13 of 72 CONFIDENTIAL  
 PROTOCOL SYNOPSIS  
Study Title  A Phase  2 Clinical Trial Comprised of a Double -Blind, Placebo -Controlled Phase 
Followed by [CONTACT_126221] -Label Phase to Evaluate the Safety and Efficacy of RZL -012 
in Subjects Seeking Fat Reduction in the Flanks (RZL -012-FL-P2US -001) 
Phase  Phase 2  
Study Drug  RZL -012 
Study Objectives and 
Endpoints  Primary Objective:  
• To assess safety and tolerability of a single RZL -012 injection session into the 
flank . 
Secondary Objectives:  
• To evaluate the efficacy of  RZL -012 treatment versus placebo treatment on fat 
reduction in the flanks  
• To assess the safety of  a second dose of RZL -012  
Primary Endpoint:  
• Evaluate safety following a single i njection session of RZL -012 vs. placebo into 
the flanks  based on AEs, laborato ry tests, ECG, and skin irritancy  
Secondary Endpoints:  
• Comparison of the proportion of flanks having an improvement as indicated by 
a score of 0 to 6 according to the Physician Global Assessment Scale (GAIS)  in 
RZL -01-treated flanks vs placebo -treated flanks . 
• Comparison of the proportion of subjects who are satisfied with treatment results  
as indicated by a yes/no satisfaction questionnaire in RZL -012-treated flanks vs 
placebo -treated flanks.  
• Comparison of the mean reduction in volume at [ADDRESS_484115] treatment vs. 
baseline for each of the treated flanks, as measured by 3D images  using the 
Canfield 3D system  in RZL -012-treated flanks vs placebo -treated flanks . 
• Ability of blinded reviewers to correctly identify, per patient, the flank treated 
with test compound (active) vs the flank treated with vehicle (placebo). Success 
will be defined as at least 70% correct identification vs the expected 50% correct 
identification based on random guessing .  
• Evaluate safety following a second dose of RZL -012 based on AEs, laboratory  
tests, ECG, and skin irritancy .  
• Characterization  of RZL -012 pharmacokinetic  (PK)  profile  
Study Design  This clinical trial is comprised of a double -blind, placebo -controlled phase 
followed by [CONTACT_3440] -label phase.  
The double -blind, placebo -controlled phase of the trial will consist of a screening 
period, baseline visit and a 12-week post -treatment follow -up period .  At the 
baseline visit, each flank (right and left) of each study participant will be 
randomized into either the active RZL -012 treatment group or the placebo group 
and each flank will receive multiple injections in a single session  of RZL -012 or 
placebo . Blood samples will be  collected for 6 of the 12 subjects for PK analyses . 
All subjects will be followed up for 12 weeks after the single treatment session.  
Upon completion of the  double -blind phase of the study , and the opening of codes 
subjects will be offered RZL -012 open -label treatment in the flank  previously 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 14 of 72 CONFIDENTIAL  
 treated with  placeb o.  Consenting subjects will be followed for safety and efficacy 
for an additional 12 weeks.  
In both the double -blind and open -label  phases of the study, s ubjects will be 
monitored for adverse events (AEs). Subjects will return to the site for visits at [ADDRESS_484116] meet all of the following 
criteria:  
1. Is a male or female subject between the ages of 18 and 65 years, inclusive.  
2. Has body mass index (BMI)  BMI of ≥ 22 and < 30 . 
3. Has clearly visible and palpable fat in the flanks  
4. Has symmetrical appearance of right and left flanks  
5. Agrees to maintain weight (i .e., within 5% of body weight)  by [CONTACT_386310].  
6. Agree to avoid exposure of the treated area to the sun for at least 1 month after 
each treatment session.  
7. If female, is not pregnant or breastfeeding based on the following:  
a. agree to the use of highly effective contraceptive methods  for at least 
[ADDRESS_484117] at screening and baseline; or  
b. is of nonchildbearing potential defined as clinically infertile as the 
result of surgical sterilization (hysterectomy, bilateral tubal ligation, 
and/or bilateral oophorectomy); or   
c. is confirmed postmenopausal status (defined as either having 
amenorrhea for ≥ 12 consecutive months without another cause , having 
documented serum follicle -stimulating hormone (FSH) level > 40 
mIU/mL, or having another documented medical condition (e .g., was 
born without a uterus) ) 
NOTE: The following are considered highly effective contraceptive 
methods: hormonal oral contrac eptives, injectables, and patches; 
intrauterine devices; double -barrier methods (synthetic condom, 
diaphragm, or cervical cap used with spermicidal foam, cream, or gel); 
and male partner sterilization.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 15 of 72 CONFIDENTIAL  
 8. If male (with or without vasectomy), agree to the use of highly effective 
contraceptive methods, e.g. condom, from study baseline until [ADDRESS_484118] day of study drug.  
9. Is willing to avoid strenuous exercise for seven (7) days post treatment.  
10. Is motivated to adhere to the visit schedule and protocol r equirements.  
11. Is willing and able to sign an Institutional Review Board (IRB) approved 
informed consent form (ICF) indicating that they are aware of the 
investigational nature of the study.  
Main Exclusion Criteria  Subjects must NOT  meet any of the following exclusion criteria to be eligible for 
enrollment:  
1. Is unable to tolerate subcutaneous injections.  
2. Has dysfunctional gallbladder activity (e.g., underwent cholecystectomy or 
cholecystitis).  
3. Has an uncontrolled systemic disease that  is not stabilized (i.e., cardiovascular 
disease, mental illness).  
4. Has used anticoagulation therapi[INVESTIGATOR_113378] (i.e., 
aspi[INVESTIGATOR_248], ibuprofen, vitamins, and herbal preparations) for seven (7) days prior 
to treatment.  
5. Has medication or a history of coagulopathy.  
6. Has a history or family history of venous thrombotic disease.  
7. Had a non -invasive fat reduction and/or body contouring procedure in the 
flanks  within the past 12 months.  
8. Has any scars, unshaven hair, tattoos, on or n ear the proposed treatment area . 
9. Has significant history or current evidence of a medical, psychological or other 
disorder that, in the Investigator’s opi[INVESTIGATOR_1649], would preclude enrollment in the 
study.  
10. Has an active dermatitis or open wound in the proposed t reatment area.  
11. Abnormal coagulation profile including: activated partial thromboplastin time 
(aPTT) > ULN, international normalized ratio (INR)  > ULN reference range 
(> 1.3), prothrombin time (PT)  > ULN . 
12. Has an active bacterial, fungal, or viral infection in the proposed treatment 
area.  
13. Has known allergic reactions to  any injectables . 
14. Has been treated chronically in the past [ADDRESS_484119] one ( 1) week prior to study entry with 
non-steroidal anti -inflammatory drugs (NSAIDs).  
16. Current participation or participation within three (3) months prior to the start 
of this study in a drug or other investigational research study.  
Dose and Dosing 
Regimen  and 
Administration of Study 
Drug  At the start of the double -blind, placebo -controlled phase of the trial each flank 
(right and left) of each study participant will be randomized into either the active 
RZL -012 treatment group or the placebo group an d each flank will be treated 
with multiple injections in a single injection session in accordance with the table 
below:  
 RZL -012 (50mg/mL 
DP injectable solution)  Placebo (Injectable sterile solution)  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 16 of 72 CONFIDENTIAL  
 Upon completion of the double -blind phase of the study, and the opening of 
codes, subjects will be offered RZL -012 open -label treatment in the flank 
previ ously treated with placebo i n the same manner as described in the table 
above .   
RZL -012/placebo  injections  – Treatment will cover the area of each 
randomized flank. A surface area of 15  cm x  6 cm will be chosen for treatment 
as per the temporary tattoo grid shown below.  
Flanks will be injected with RZL -012/placebo with the needle pointing 
perpendicular (90°) to  skin surface. An ice pack will be placed on the injected 
area for pain relief immediately after injections are completed. Subjects will 
remain in injection position for an additional 10 minutes after dosing.  
The injection pattern will be based on the foll owing grid in which the distance 
between rows and columns will be 1.5 °cm, as seen below.  
In the previous clinical studies , the injection dose at each of the injection points 
was 5.1 °mg for a low dose and 7.5°mg for a high dose  with a distance of 1 °cm 
between the injection points. In the current study , a dose of 7.5 °mg is planned to 
be administered in each injection point with a distance of 1.5 °cm between each 
of the points.  
 
 
Needles of  27 G (1 inch needle length) will be used  to allow delivery  into the 
depth of fat tissue.  Randomized Right or 
left flank  12 12 
Single Treatment * 55 injections at 
7.5mg/0.15mL per 
each injection point –
A total of 412.5 
mg/8.25 mL total dose 
per flank  55 injections at 0.15mL per each 
injection point –A total volume of 
8.25 mL total dose per flank   
* 55 injections is  the maximum number of injections. In case of smaller flank s, the 
number of injections may be lower.  
 
Dose Justification  The maximal dose of RZL -012 administered to subjects to date was 270  mg via 36 
injections of 7.5 mg/0.[ADDRESS_484120] and the amount 
given  per injection site w ere well tolerated and  not associated with any significant 
safety issues. To cover the flank area in the current study, the maximal  dose will be 
increased to 412.5  mg per session via 55 injections of 7.5  mg/0.15  mL per injection 

Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 17 of 72 CONFIDENTIAL  
 site with the distance between injection sites of 1.5  cm. Subjects who receive a 
second  RZL -012 dose will receive a maximal RZL -012 dose of 412.5 °x°2=825 mg 
across 2 dosing sessions , with  a 3-month interval between injection sessions .     
The maximal dose of RZL -012 administered to non -rodents (pi[INVESTIGATOR_14107]) to date was 
1,000  mg via 40 injections of 25  mg/0.5  mL per injection, with the distance 
between injection sites  being 1 -2 cm. This dose was given monthly  at 4 injection 
sessions per pig , with every month ly injection administered to the contralateral 
side, and was well tolerated without any significant systemic or local side effects . 
Dosing pi[INVESTIGATOR_22736] 4 °x°1,000  mg is equivalent to about 4°x°900 mg in human s, based 
on body surface area calculations . These preclinical studies provide a good margin 
vs anticipated human dosing both in terms of the total dose, dosing frequency (once 
monthly in pi[INVESTIGATOR_386299] 3 months in h umans)  and amount per injection site 
(25°mg in pi[INVESTIGATOR_386300] 7.5 °mg in humans).  
Safety Analysis  The assessment of s afety will be based on AEs which will be recorded throughout 
the study until the final study visit .  In case of ongoing AEs at the final study visit  
an unscheduled visit will be scheduled for further follow -up.   
The assessment of safety will also include  vital signs and treatment area evaluation. 
Treatment area evaluation includes, but is not limited to, evaluation of edema, pain, 
bruising, erythema,  induration, numbness, paresthesia, tenderness, and pruritus. 
ECG and laboratory  tests including D -dimer, hematology and chemistry will be 
conducted  at the [ADDRESS_484121] deviation, median, minimum and maximum for means of 
variables by [CONTACT_30157].  
The data will be analyzed using the SAS ® version 9.4 (SAS Institute, Cary North 
Caro lina).  
Primary Endpoints:  
1- Adverse events will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA, most updated version) terminology and presented in 
tables by [CONTACT_1196] (SOC) and Preferred Term (PT).  
2- AE data will be listed individually and summarized by [CONTACT_386311] a system organ class.  
3- Skin irritancy AEs related to the injection procedure will be evaluated for 
frequency, severity and duration  by [CONTACT_1570].   
4- Fisher's Exact test will be applied for testing the statistical significance of 
the difference in percent of subjects  that experienced  Skin irritancy AEs 
related to the injection procedure  between the study groups.  
5- Laboratory tests and ECG results will be summarized in appropriate table s. 
Secondary Endpoints:  
• GAIS  
• Flank volume reducti on from baseline to week 12, assessed by [CONTACT_386312] (GAIS).  T he proportion of subjects for whom an 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 18 of 72 CONFIDENTIAL  
 improvement in GAIS as indicated by a score of 0 to 6 will be compared in RZL -
012-treated flanks  vs placebo -treated flanks,  
Fisher's Exact test will be applied for testing the statistical significance of the 
difference in percent of subjects for whom an improvement in GAIS was 
observed between treatment groups.  This w ill be calculated along with 95% 
exact confidence interval by [CONTACT_22058] t group.  
• Correct pre and post-treatment identification  
The proportion of blinded reviewers able to correctly differentiate between 
treated flanks  will be calculated along with 95% exact confidence interval by 
[CONTACT_1570].  
• Satisfaction (Yes/No questionnaire ) 
The proportion of satisfied subjects will be calculated along with 95% exact 
confidence intervals for each treatment group.  Fisher's Exact test will be 
applied for testing the statistical significance of the difference in percent of 
satisfied subjects between treatment groups.  
• Reduction in Volume  
The change and relative change from baseline in Flank volume as measured by 
[CONTACT_386313] [ADDRESS_484122] for two means (paired observations)  will be applied for 
testing the statistical significance of the change and relative change from 
baseline at  week 12 in flank volume betw een treatment groups . 
Study Duration  Double -Blind Phase : each subject will participate in the study for 4 months, which 
comprises a screening period, baseline/treatment period, and follow up period.  
Open -Label Phase : Subjects who  choose to continue with the open -label phase of 
the study  will be followed up for an additional 3 months.  
Study Centers  This will be a single center study  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484123] the effects of RZL -012 injection on fat accumulation in the flank area (the 
lower back).  
Raziel Therapeutics , Ltd. (Raziel)  has discovered that a novel synthetic molecule (termed RZL -
012) can help reduce fat content in human s and pi[INVESTIGATOR_386301].  The suggested mechanism of action (MOA) of RZL -[ADDRESS_484124] ex cess fat tissue at selected anatomical sites . 
To date, Raziel has conducted several clinical studies under INDs to evaluate the safety and 
efficacy of RZL -012 for local fat reductions, including obesity (INDs 119941, 133324), lipomas 
of Dercum’s Disease pa tients and SMF (IND 135762) and SMF reduction (IND 154260). Based 
on the results of these studies, Raziel concluded that the safety profile of RZL -012 is good and 
acceptable and the compound demonstrated efficacy in long -term reduction of local 
subcutaneou s fat .  
Based on the clinical study results received to date, Raziel continues to investigate the efficacy 
and safety of RZL -012 for the treatment of fat accumulatio n in larger parts in the body such as 
the flanks . 
Chemically, RZL -012 is 5-(3,6-dibromo -9H-carbazol -9-yl)-N,N,N -trimethylpentan -1-aminium 
chloride . RZL -[ADDRESS_484125] is > 97% pure . 
The molecular weight is 488 gr/mole and its structural formula , C20H25Br2CIN 2, is illustrated in 
Figure 1 below . 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 20 of 72 CONFIDENTIAL  
 Figure 1:  Structural Formula of RZL -[ADDRESS_484126] was manufactured in Patheon (Italy) and packed and labeled at 
ThermoFischer, [LOCATION_003]. The drug product is provided in vials of 240  mg/4.8  mL (50 °mg/mL) .  
The active ingredient and formulation manufacturing and packing were in accordance with 
current Good Manufacturing Practices (cGMPs).  
RZL -012 is provided as a sterile liquid solution suitable for injection.  The quantitative 
composition of RZL -012 is liste d in Error! Reference source not found.  below.  
Table [ADDRESS_484127] caused liponecro sis at the injection site, followed by a transient 
inflammatory response and finally by a healing process in which fibrotic tissue replaced previous 
Component  Concentration (mg/ml ) 
RZL -012 50  
Tween -80 100 
Propylene glycol  570 
Benzyl alcohol  30 
Water  250 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484128] level (NOAEL) safety data obtained during animal testing . 
[IP_ADDRESS].  In-vivo Efficacy Studies  
A GLP study was conducted to evaluate the potential local and systemic toxicity, as well as 
efficacy of RZL -012, in domestic Yorkshire crossbred swine. Twent y-eight pi[INVESTIGATOR_386302] (0.9% Sodium Chloride for Injection) or 500 mg (20 injections of 25 mg RZL - 012) 
RZL -012 and observed 24 hours (3/group/sex), 14 days (2/group/sex), or 84 days (2/group/sex) 
post dose. Study results demonstrated that 84  days after dosing, the mean fat thickness in RZL -
012-treated males was reduced approximately by 16.8% as compared to a 1.1% increase in males 
treated with Saline. The mean fat thickness in females treated with RZL -012 was reduced 
approximately by 19.1% as  compared to a 3.7% increase in females treated with Saline. This 
study also contributed to the understanding of RZL -012 MOA. Since all injection sites (20 
injection sites/pig) were quantified for necrosis, inflammation and fibrosis it was possible to 
demo nstrate injection -related fat tissue damage followed by [CONTACT_296304] [ADDRESS_484129] dose. In essence, injection of RZL -
012 resulted in a long -lasting replacement of fat tissue by [CONTACT_386314] d tissues.  
[IP_ADDRESS].  Safety Pharmacology  
The effect of RZL -012 on the central and peripheral nervous systems was evaluated using the 
Functional Observational Battery (FOB) in male Sprague Dawley rats. RZL -012 was 
administered subcutaneously to rats (n = 8/group) as 10 mg/rat. From the results, it was 
concluded that RZL -[ADDRESS_484130] any of the central nervous system (CNS) functions tested 
using FOB in rats.  
The effect of RZL -012 was evaluated on respi[INVESTIGATOR_386303] -out p lethysmography. RZL -012 was administered subcutaneously at a fixed dose of 
10 recorded to cover the entire predetermined time points: Pre -dose, 1, 2, 3, and [ADDRESS_484131] any of the parameters tested; hence, it was concluded tha t RZL -012 
has no effects on the respi[INVESTIGATOR_386304] 10 mg/rat.  
A board -certified veterinary cardiologist conducted a qualitative and quantitative review of the 
electrocardiograms (ECGs) obtained pretest, pre -dose, [ADDRESS_484132] -dose following the 
subcutaneous injection of 500 mg 5.0% RZL -[ADDRESS_484133] of the subcutaneous injection of 5.0% RZL -012 on qualitative or 
quantitative ECG parameters or blood pressure.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 22 of 72 CONFIDENTIAL  
 1.2.2.  Toxicology  
[IP_ADDRESS].  Single and multidose Toxicity Studies  
[IP_ADDRESS].1.  Rats  
Single  subcutaneous  administration  of test item RZL -012 at the doses  of 5, 10, and 20 mg/rat  
(about  20, 40 and 80mg/kg)  in Sprague -Dawley  rats resulted  in non-systemic  effects  and/or  local  
effects  at the treated  skin area.  Few changes  observed  in hematological  parameters  (changes  in 
white  blood  cells [WBC]  count,  neutrophils,  monocytes  and eosinophils)  were  considered  
secondary  effects  due to inflammatory  response  (local  skin reactions).  The changes  observed  in 
clinical  chemistry  parameters  (increased  blood  urea nitrogen  [BUN]  in males  and females  and 
increased  creatinine  and aspartate  aminotransferase  [AST]  levels  in females)  at all the doses  
tested  and histopathological  changes  in kidneys  (necrosis  in tubular  epi[INVESTIGATOR_2130])  at 20 mg/kg  
were  considered  systemic  effects.  Methods  and results  from  the extended  single  dose toxicity  
study  are described  in the Investigator’s  Brochure  (IB).  
Considering skin changes as non -systemic effects and/or local effects, the NOAEL was 
determined at 5 mg/rat (approximately 20 mg/kg) under the test conditions and doses employed.  
In the 6-month chronic  rat study  (Study No. G20648 ), 7 monthly subcutaneous administration s 
of RZL -012 for 6 months in Sprague -Dawley rats were well tolerated systemically in both male 
and female rats up to the high doses tested in both males (21.4 mg/rat) and females (14.98 
mg/rat) which equated to an average mg/kg rat dose of 41.36 mg/kg in males and 49.08 mg/kg in 
females . Gross changes we re observed at the injection sites in both sexes (males slightly worse 
possibly due to larger amounts of RZL -012 injected due to increased body weight compared to 
the females) at the end of  the treatment period such as wound thickening and discoloration with 
inflammation, epi[INVESTIGATOR_3915]/dermal necrosis, epi[INVESTIGATOR_386305] . Some of these local findings were test article (TA) related (inflammation, 
hyperplasia) while others  were considered secondary to self -inflicted local inj uries attempted by 
[CONTACT_386315] a consequence of the irritation  caused by [CONTACT_386316]/vehicle administration.  
[IP_ADDRESS].2.  Pi[INVESTIGATOR_386306],  RZL -012 (50 mg/m L), in domestic  Yorkshire  crossbred  swine  
following  one subcutaneous  injection  into the subcutaneous  abdominal  fat on Day 0. Methods  
and results  from  this extended  single  dose toxicity  study  are described  in detail  in the IB. 
Assessment  of toxicity  was based on mortality,  clinical  observations,  body  weight,  qualitative  
food consumption,  body  temperature,  subcutaneous  fat temperature,  blood  pressure,  physical  and 
electrocardiographic  examinations,  and anatomic  and clinical  pathology.  Blood  samples  were  
colle cted and analyzed  for porcine  stress  syndrome  testing  and toxicokinetic  assessment  of the 
test article.  
Administration of the test article was not associated with any mortality, clinical observations 
(with the exception of transient redness and swelling at  injection sites), body weight or food 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 23 of 72 CONFIDENTIAL  
 consumption changes, effects on electrocardiographic endpoints, or changes in clinical chemistry 
or coagulation parameters.  
In the 3 -month GLP pig study, Yorkshire swine were administered 250, 500 and 1000 mg/pig of 
RZL -012 on Study Days 1, 29, 57 and 85. RZL -012 administration was systemically well 
tolerated at all dose levels .  Significant local irritation was seen at injection sites (including 
placebo to a lesser extent) caused by [CONTACT_386317]/or vehicle. 
Macroscopic findings at the injection sites included abrasions, skin scabs, and reddened skin and 
microscopic findings included  fibrosis, inflammation, degeneration/necrosis, atrophy and 
regeneration of the muscularis carnosus and fibrosis and inflammation of subcutaneous tissue. 
The lesions were still present after an [ADDRESS_484134] any effects on the animals’ body weight/food consumption 
or other endpoints with the exception of two males (1 each, mid and high dose) having a mild 
increase in neutrophils (increased bands) considered due to the inflammatory respon se noted 
histologically. The only other finding was cytoplasmic vacuolation in the pancreas seen at a 
minimal level in multiple animals in all dose groups (including controls) with a higher severity 
(mild; 1 male, moderate 1 male; marked 1 female) in 3 /[ADDRESS_484135] level (NOAEL) for RZL -012 of 1000  mg/pig when injected 4 times, 
with an interval of 1 month between injections  sessions . The establishment of the NOAEL was 
based upon the  microscopic effects being limited to the subcutaneous tissue with no systemic 
effects and the evidence of complete healing at 84 Days.  
[IP_ADDRESS] Reproduction toxicology studies  
Rat embryo -fetal Development (EFD) and Fertility and Early Embryo -fetal Development (FEED; 
fertility) studies have been conducted with RZL -012.  
In the EFD study , structural and / or other abnormalities were evaluated in fetuses of pregnant rats 
injected SC with 2.5 to 20 mg/rat RZL -012 on gestations days 5, 8, 11, & 14.  
Maternal parameters comprising of mean uterine weights, number of corpora lutea, implantation s, 
and early and late resorptions/deaths and litter parameters (mean fetal weight and number of live 
fetuses were comparable between  the placebo control  group and treated groups up to the highest 
dose of 20 mg/rat . No test item -related changes were observe d during external  or fresh visceral 
observations of  the fetuses and t here were no skeletal malformations observed in any litter at any 
of the tested dose levels. Variants and anomalies observed in various skeletal components across 
RZL -[ADDRESS_484136] Level s (NOAEL) for m aternal toxicity is 5 mg/rat  (15.3mg/kg)  
due to a treatment -related reduction in body weight and food consumption at > 10 mg/rat  and the 
NOAEL for e mbryo -fetal developmental toxicity is 20 mg/rat as the cesarean section and litter 
parameters were unaffected  by [CONTACT_386318] 20 mg/rat  (62.5mg/kg) . 
In the rat fertility study, functional effects (e.g., on libido, epi[INVESTIGATOR_386307], 
effects on the estrous cycle, tubal transport, implantation and development of pre -implantation 
stages of the embryo in females) were evaluated in male and female rats injected SC with 2.5 to 
20 mg/rat RZL -012 on Study Days 1, 8, 15 and Gestation Day 7 in the females and 1, 8, 15, 22, 
29, 36 and 43 in the males.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484137] implantation losses, mean number of 
fetuses, gross and histopathology were unaffected by [CONTACT_386319] d oses.  
Subcutaneous administration of up to 20 mg/rat RZL -[ADDRESS_484138] Level (NOAEL) for males and females was considered to be 10 -20 mg/rat/injection 
session (average mg/kg dose of 50.5 mg/kg for males and 46.2 mg/kg for females) when 
administered at weekly intervals  
1.2.3.  Clinical Studies  
To date, safety data on RZL -012 has been collected from 6 clinical trials. The enrolment  for an 
additi onal study for the indication of Submental Fat (SMF) is ongoing (study RZL -012-SMF -
P2b-us-001) and will be completed by [CONTACT_466] 2021. Since the SMF trial includes a placebo -
treatment group and is blinded, safety data is presented for the first [ADDRESS_484139].  
A summary of the clinical studies conducted by [CONTACT_386320] 2 
below.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 25 of 72 CONFIDENTIAL  
 Table 2 Overview of Ongoing and Completed Clinical Studies  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484140] in 
Overweight, 
Healthy 
Volunteers  A randomized, 
double -blind, 
vehicle -
controlled, 
dose-escalation 
study with 8 
subjects, 6 
active and 2 
control, in each 
of the 3 
cohorts.  Cohort 1: 5 mg  
Cohort 2: 10 mg  
Cohort 3: 20 mg  
 Healthy, 20 -
40 years 
old, 
overweight 
by [CONTACT_386321] 
(BMI) 
definiti on 
(25 < BMI 
≤ 34.9), 
adult males.  
 18 RZL -012 (5 -
20mmg)  
6 Placebo  
IND 133324  
RZL -012-
P2aUS -001.4  
 
 
COMPLETED  
 2a A Double 
Blind, 
Randomized, 
Placebo 
Controlled, 
Dose 
Escalation 
Phase 2a 
Clinical Trial 
for the 
Evaluation of 
Safety and 
Thermogenesis -
induction of 
RZL -012 in 
Overweight and 
Obese 
Volunteers  A randomized, 
double -blind, 
placebo -
controlled, 
dose-escalation 
study with 8 
subjects, 6 
active and 2 
control, in each 
of the 4 
cohorts.  
 Cohort 1: 40 mg  
Cohort 2: 80 mg  
Cohort 3: 120 m g 
Cohort 4: 180 mg  
 Adult male 
subjects 20 –
60 years 
old, with 
27.5 < BMI 
≤ 34.9  24 RZL -012 
(40-180mg)  
9 Placebo  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 27 of 72 CONFIDENTIAL  
 IND 135762  
RZL -012-FD-
P2aUS -001.7  
 
 
COMPLETED  2a An Open Label, 
Phase 2a 
Clinical Trial 
for the 
Evaluation of 
Safety and 
Efficacy of 
RZL -012 for 
the Treatment 
of Women with 
Lipedema 
Involving 
Substantial Fat 
above the Knee 
or of Women 
and Men with 
Nodular 
Dercum’s 
Disease  Open -label 
safety and 
efficacy 
clinical trial  
6 active 
subjects in each 
cohort  Cohort 1: Patients 
received up to 40 mg 
RZL -012  
Cohort 2: patients 
received [ADDRESS_484141]-
menopausal 
(at least 2 
years) 
women no 
more than 
65 years 
old, with 
lipedema 
involving 
substantial 
fat above 
the knee or 
nodular 
Dercum’s 
disease in 
such women 
and in men 
20–65 years 
with 
nodular 
Dercum’s 
disease  DD: 6 RZL -012 
up to 40mg  
Lipedema: 6 
RZL-012 60 -
80mg  
IND 135762  
RZL -012-SMF -
P2A-US-001.2  
 
COMPLETED  
(Study report 
filed to IND 
154260)  2a A Single Blind, 
Randomized, 
Placebo -
controlled, 
Phase 2a, 2 -
cohort Study 
for the 
Evaluation of 
Safety and 
Efficacy of 
RZL -012 for 
Submental Fat 
Reduction in 
Healthy 
Volunteers  A single blind, 
2-cohorts (8 
active vs. 4 
control in 
cohort 1 and 10 
active vs. 6 
control in 
cohort 2),  to 
test safety and 
efficacy in 
healthy 
subjects  Cohort 1: RZL -012 
subjects were dosed in a 
range of 70 -90mg, based 
on SMF fullness. Cohort 
2: RZL -012 subjects 
were dosed in a range of 
125-210mg, based on 
SMF fullness.  Men and 
women 18 -
65 years old  18 RZL -012 
(70-210mg)  
10 Placebo  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 28 of 72 CONFIDENTIAL  
 IND 135762  
RZL -012-DD-
P2B-US-001.4 ,  
 
COMPLETED  
 2b A Double 
Blind, 
Randomized, 
Multi -Center, 
Placebo -
Controlled 
Phase 2B 
Clinical Trial 
for the 
Evaluation of 
Efficacy and 
Safety of RZL -
012 in Subjects 
having 
Dercum’s 
Disease (DD) 
Lipomas  A double blind 
clinical study 
to test efficacy 
and safety in 
DD subje cts 
with painful 
lipomas  
A total of 38 
subjects with a 
randomization 
ratio of 1:[ADDRESS_484142] 4 
lipomas/nodules, 
preferably 6, and no 
more than 8, are injected 
per subject. Dosing is 
according to lipoma size, 
where the total injected 
dose does not exceed 
240 mg per patient (48 
injections of 
5mg/injection).  Women and 
men, 18 - 70 
years old, 
diagnosed 
with DD 
having 
lipomas  Double blind:  
20 RZL -012 
(40-200mg)  
18 Placebo  
 
Open label:  
9 RZL -012(60 -
170mg)  
IND 135762  
RZL -012-
hADMEC14 -
001 
COMPLETED  
 1 An Open -
Label, Single -
Dose Study to 
Assess the 
Absorption, 
Metabolism, 
Excretion, and 
Mass Balance 
of 
subcutaneous 
[14C] -RZL -012 
in Healthy 
Adult Male 
Subjects  
 This is an 
open -label, 
single -
treatment 
session study 
with 
multi -injections 
to assess the 
absorption, 
metabolism, 
excretion, and 
mass balance 
of RZL -012. A 
total of 6 
subjects were 
enrolled and 
were followed 
up for up to 28 
days from 
injection  
 ~72.9 mg RZL -012 
containing 
[14C] -RZL -012 
(~71.4  µCi) 
(1.6 mL x [45.54  mg/mL  
solution for SC 
injection)  Healthy, 
adult, male, 
19-55 years 
of age  6 RZL -012 
(72.9mg)  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 29 of 72 CONFIDENTIAL  
 IND 154260  
RZL -012-SMF -
P2b-us-001 
On-Going  2b A double blind, 
randomized, 
three -arm, 
placebo -
controlled 
Phase 2b study 
to evaluate the 
efficacy and 
safety of RZL -
012 in subjects 
seeking 
submental fat 
reduction 
(RZL -012-
SMF -P2bUS -
001) Phase 2b, 
double -blind, 
randomized, 
three -arm, 
placebo -
controlled 
study.  Subjects 
will receive a 
single 
treatment 
session that 
consists of 
multiple 
injections of 
RZL -012 or 
placebo into 
the submental 
area under the 
chin, after 
which they will 
be monitored 
for safety and 
efficacy over 
84 days. A total 
of 135 subjects 
will be 
enrolled.  1. RZL low dose 
– dose of 163 .2±20.4 
mg/subject spreads over 
32±4 injection points  
2. RZL high dose 
– dose of 
240±30mg/subject 
spread over 32±4 
injection points  
3. Placebo – 
volume of 4.8±0.6ml 
vehicle/subject spread 
over 32±[ADDRESS_484143] 
consented to 
participate 
in this study  74 RZL -012 
and placebo 
(142.8mg -
270mg)  
 
 
[IP_ADDRESS].1.  Protocol No. RZL -012-P0US -001.3 Status: Completed  
The first-in-man clinical trial was an exploratory, randomized, double -blind, vehicle -controlled 
Phase 0 study, conducted under IND 119941, to evaluate the safety and thermogenesis -induction 
of three escalating doses of RZL -012 in overweight and obese subjects. This study also evaluated 
the RZL -012 pharmacokinetics from the baseline visit (Day 0) through Day 1.  
The primary objective of the study was to evaluate the overall safety of RZL -[ADDRESS_484144] was 
defined as an increase of 1 °C in the injected site when compared to the surroundi ngs and/or the 
contra -lateral (non -injected site), apparent at least 28 days after injection. This was monitored by 
[CONTACT_214032] (± 0.1 °C) Infra -Red thermal camera.  
The secondary objective was the determination of RZL -012 pharmacodynamics. The evaluation 
of the extent, duration and tissue associated changes of the thermogenic response to RZL -012 via 
minimal invasive means, including injected -site thermogenesis imaging, Magnetic Resonance 
Imaging (MRI) and punch biopsy, following injection into t he subcutaneous fat are summarized 
below.  
The study was composed of [ADDRESS_484145] was injected with 
either RZL -012 (6 subjects) or vehicle (2 subjects). This was a dose escalation study; therefore, 
RZL -012 was injected  at doses of 5, 10, and 20  mg/subject at cohorts 1, 2, and 3, respectively. 
Subjects received a single treatment in multiple sites (1 - 4) of injection diagonally (45°) to the 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 30 of 72 CONFIDENTIAL  
 skin surface at 3 centimeter ( cm) lateral to the umbilicus lateral wall. The distance between 
injected sites was 1  cm (see Figure 2).  
Figure 2:  Injection Sites for Phase 0 Study  
 
 
 
 
RZL -012-P0US -001.3  Study  Results:  
RZL -[ADDRESS_484146] in the lower abdomen at the surrounding of 
injected side (but away from the injected site).  
One systemic AE involved a  severe elevation of  alanine transaminase  (ALT ) blood levels and a 
moderate elevation of AST blood levels [ADDRESS_484147] dose (AST 
169 U/L; ALT 411 U/L) of active treatment. This elevation was transient. Resolution for AST 
eleva ted levels and reduction for ALT levels to Grade 1 according to MeDRA coding dictionary 
occurred 11 days following detection. ALT levels were normal on the next visit on Day 56. 
Other liver enzymes such as GGT and alkaline phosphatase, as well as bilirubin  levels remained 
within normal range. There were no other systemic clinically significant AEs.  
PK profile results demonstrated an association between dose and C max with values of 
13.11  ng/mL at the lower dose level (Cohort 1), 23.02 ng/mL at the next (doub le) dose level 
(Cohort 2) and 51.46 ng/mL at the highest (x4 of the lowest dose) dose level (Cohort 3).  
The exploration of thermogenesis induction by [CONTACT_296308] -012 in humans was successful. A raise in 
temperature at the injection site was mostly evident in cohor t 3 (the highest dose) at Day 14 or 
Day 21 following injection in RZL -012 treated subjects only.  
MRI results demonstrated a decrease over time in Subcutaneous Fat Mass (SFM) ratio 
(injected/non -injected side) vs baseline in most RZL -012 treated subjects of  Cohort 3. This 
reduction was not statistically significant. Biopsy did not yield enough tissue (because punch 
biopsy did not penetrate deep enough to reach the remodeled tissue) and therefore it was not 
possible to demonstrate changes in the adipose tissu e. 
Raziel concludes that the potential risk -benefit balance for RZL -012 is favorable, and it is likely 
that higher doses of RZL -012 will generate better results.  

Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 31 of 72 CONFIDENTIAL  
 [IP_ADDRESS].2.  Protocol No. RZL -012-P2aUS -001.4 Status: Completed  
An additional clinical trial was a double -blind, randomized, placebo controlled, dose escalation 
Phase 2a study, conducted under IND [ADDRESS_484148] 28 days after injection, at the injected site 
compared with the con tra-lateral, non -injected site.  
The secondary objective was the determination of RZL -012 pharmacodynamics and 
pharmacokinetics. The secondary efficacy endpoints included the following:  
1. Duration of the thermogenic effect, defined as a net -delta ≥ 1. 
2. Local reduction in fat mass as determined by [CONTACT_9268].  
3. Clinical laboratory changes from baseline.  
4. Establishing the PK profile for RZL -012. 
5. Anthropometric changes from baseline.  
6. Elucidation of the histological changes that may  account for the thermogenic effect by 
[CONTACT_386322].  
7. Change from baseline in inflammatory markers and cytokines.  
The study was composed of 4 cohorts. Each cohort was designed to enroll 8 subjects (6 active 
and 2 control). In Cohort 3, [ADDRESS_484149]’s dropout. The overall number of subjects in the study was 33.  
Subjects received a single treatment at multiple sites (8 - 36) of injection diagonally (45°) to the 
skin surface at  5 cm lateral to the umbilicus lateral wall. The distance between injected sites was 
2 cm in cohorts 1 - 3 and 1 cm in Cohort 4 as seen in Figure 3.  
Figure 3:  Injection Sites for Phase 2A Study  
 
 
 
 
RZL -012-P2aUS -001.4 Study Results:  
In this study, in which significantly higher doses were tested (up to 180 mg), RZL -[ADDRESS_484150] 

Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484151] injected dose of 180 mg. However, this increase was transient, up to 3  days 
after injection, and non -clinically significant.  Further review of coagulation parameters revealed 
there was no clinically significant activation of the coagulation system nor any presence of 
Disseminated Intravascular Coagulation (DIC). The absence of any clinical symptoms related to 
elevation of D -dimer supports a direct link between RZL -012 induced i nflammation and elevated D -
dimer levels, unrelated to venous thromboembolic disease  
Biopsies taken from two injection sites revealed no damage to the skin 56 days following RZL -
012 injection. Based on the histology results, the process that seemed to be do minant is fat 
necrosis and infiltration of macrophages into the necrotic fat tissue that resulted in a replacement 
of the local fat tissue by [CONTACT_296310].  
A decrease from baseline in SFM ratio (injected/non -injected side), as assessed by [CONTACT_9268], was 
noted  in RZL -012 treated subjects of Cohorts 2 – [ADDRESS_484152] injection, a clear reduction in SFM was noticed ( -14.32%). Cohort [ADDRESS_484153] reduction in SFM at Day 56 ( -18.10%).  
There were no major changes over time and no specific trend to suggest a dose cor relation 
response in any of the parameters of lipid profile (TC, TG, LDL, HDL, and FFA) and fasting 
glucose.  
The PK profile of RZL -012 demonstrated dose proportionality. The maximal plasma 
concentration of RZL -012 was less than than 0.5 µg/mL (500 ng/mL) in all subjects and T max 
was obtained at about 2 hours following injection . 
No significant decrease in BMI or in subjects’ weight values was evident in all cohorts, 
compared to vehicle injected subjects. There was no consistent pattern to suggest an association 
between inflammation markers and cytokines levels. Therefore, the inflammation reaction due to 
macrophag e infiltration into the necrotic tissue seems to be local and without any systemic 
effect.  
Raziel concluded that the risk benefit profile of RZL -012 as seen in the clinical trials to date, is 
in favor of RZL -012. RZL -012 may be useful in treating condition s in which removal of excess 
fat is desired (i.e., excess in SMF ). 
[IP_ADDRESS].3.  Protocol No. RZL -012-FD-P2aUS -001.7  Status: Completed  
An additional clinical trial was an open label Phase 2a study conducted under IND 135762 to 
evaluate the safety and efficacy of RZL -012 for the treatment of women with lipedema involving 
substantial fat above the knee or of women and men with nodular Dercum’s disease (DD).  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 33 of 72 CONFIDENTIAL  
 The primary objective was to evaluate the overall safety of RZL -012 following injection into the 
subcutaneous fat in patients with lipedema or DD.  
The secondary objective was to evaluate local fat reduction, its extent, duration and tissue 
associated changes, in response to RZL -012 treatment, utilizing minimal invasive means 
(ultrasound) following subcutaneous injection of RZL -012 into fatty tissue below the skin.  
The study was composed of 2 cohorts. Cohort 1 was comprised of 6 subjects with DD and 
Cohort 2 was comprised of lipedema subjects having substantial fat above the knee.  
Cohort 1 (Subjects with DD) : 
Several lipom as were injected per subject. Dosing was calculated according to the size of the 
nodule (diameter), reaching a maximal dose of [ADDRESS_484154].  
Subjects received a single treatment in multiple sites (2 - 8 cm lipoma size) of injection 
according to the d esign in Figure 4. 
Figure 4:  Injections Diagram According to Lipomas Size  
 
 
 
 
Cohort 2 (lipedema subjects with substantial fat above the knee):  
The first 3 subjects received 30 mg RZL -012 in 6 injections (0.1 mL each) in one leg followed 
by 30 mg RZL -012 (6 injections, 0.1 mL each) in the second leg, for a total of 12 injections of 60 
mg RZL -012 (see Figure 5 for injection sc heme).  
The last 3 subjects received 40 mg RZL -012 in 8 injections (0.1 mL each) in one leg followed by 
40 mg RZL -012 (8 injections, 0.1 mL each) in the second leg, for a total of 16 injections of 80 
mg RZL -012 ( Figure 5).  

Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 34 of 72 CONFIDENTIAL  
 Figure 5:  Injection Scheme Lipedema Subjec ts 
 
 
 
 
 
 
RZL -012-FD-P2aUS -001.7 Results:  
Overall, [ADDRESS_484155] incidence were injection site pain and headache, each of which was 
reported by 3 of 12 subjects (25%). Pain, contusion, sleep disorders/insomnia, and muscle 
spasms were each reported by 2 of 12 subjects (16.7 %). All remaining AEs were reported by 
[CONTACT_386323].  
There were [ADDRESS_484156], and 
included swelling (injection site, joint swelling, peripheral swelling) and pain. Following an 
inves tigation by [CONTACT_079], it was found that the subject had a tendency to scratch 
or rub painful lipomas and, therefore, following compound injection, lipoma scratching led to 
swelling and pain in the injected lipomas as well as in the surrou nding areas. Most severe AEs 
resolved within 14 days after injection and the AE of pain resolved at 35 days. No medical 
intervention was required.  
Measurements  of lipoma  size in 6 DD subjects  included  ultrasound  measurements  of height,  
width  and length  for 21 injected  lipomas.  Lipoma  surface  area was calculated  by [CONTACT_386324].  Lipoma  height  was the dominant  parameter  when  referring  to its 
dimensions  as it included  aesthetic  considerations  and pressure  application  on nerves.  The mean 
reduction  in lipoma  height  on day 56 after injection  versus  baseline  was -47.9±44.1%  (P<0.001).  
The mean  change  in surface  area versus  baseline  was 30.4±82.5%  (NS).  
Lipoma  pain was measured  by [CONTACT_386325] 19 of 21 injected  lipomas  in 6 DD 
subjects  (specific  pain assessment  per each lipoma).  The mean  reduction  in lipoma  pain on day 
56 after injection  versus  baseline  was 70±36.9%  (P<0.0001).  Sixteen  (16) lipomas  reported  
having  lower  pain scores  compared  to baseline  and only 3 remained  without  change.  
Fat thickness  in 6 lipedema  subjects  was evaluated  by [CONTACT_386326] 84 injection  points  ([ADDRESS_484157]).  The mean  reduction  in 
fat thickness  on day 56 after injection  as compared  to baseline  was approximately  7% (NS).  No 
improvement  was noted  in quality  of life (QOL)  measurements.  

Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 35 of 72 CONFIDENTIAL  
 Based on the study results, Raziel concluded that RZL -012 could be beneficial in treating 
patients with fat disorders such as DD.  
[IP_ADDRESS].4.  Protocol No. RZL -012-SMF -P2aUS -001.2 Status: Completed  
An additional study was a single blind, randomized, placebo -controlled, phase 2a, 2 -cohort study 
for the evaluation of safety and efficacy of RZL -012 for SMF  reduction in healthy volunteers 
was conducted under IND 135 762. 
The primary objective was to evaluate safety following injection of RZL -012 vs. placebo 
injection into SMF . Skin irritancy and AEs related to injection procedure were mainly evaluated 
for its frequency, severity and duration. Specifically, the assessm ent of the following AEs was 
monitored: bruising, pain, induration erythema and swelling/edema.  
The following secondary endpoints evaluated treatment efficacy of active treatment versus 
placebo subjects : 
1. Reduction from baseline in SMF  volume, as measured with MRI on Day 84 as compared 
to screening, in RZL -012 treated subjects versus placebo treated subjects.  
2. Improvement of Physician’ global assessment questionnaire for treatment efficacy in 
active versus p lacebo treated subjects on Day [ADDRESS_484158]’s satisfaction rating by [CONTACT_296316] -Q 
questionnaire (Satisfaction of chin) on Day 84 visit to evaluate treatment response among 
RZL -012 t reated subjects versus placebo treated subjects.  
Twenty -Eight (28) subjects (12 for cohort 1 and 16 for cohort 2) were included in the study. 
Subjects in each cohort were injected with a different dose.  Subjects in each cohort were 
randomized in a ratio o f 2:1 of active versus placebo. A total of 28 subjects were enrolled in 
2 clinical sites. Subjects were blinded to study treatment while physicians were not blinded.  
Cohort  1 (N=12)  – Each  subject  was dosed  with up to 120 mg RZL -012 (depending  on SMF  
area)  or up to 2.4 mL of vehicle.  Averaged  injected  dose was 80 mg. 
Cohort 2 (N=16) – Each subject was dosed with up to 240 mg RZL -012 (depending on SMF  
area) or up to 4.8 mL of vehicle. Averaged injected dose was 158.5 mg.  
The injection  pattern  in both cohorts  was based  on a submental  area shaped  grid in which  the 
distance  between  rows  was 1cm and distance  between  columns  was also was 1 cm as seen in the 
figure  below.  Physicians  chose  two points  at the edge  of the 50-point  pattern  that were  not 
injected  (up to 48 injections)  as seen in Figure  6 below : 
 
Figure 6:  Diagram of Injection Pattern  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 36 of 72 CONFIDENTIAL  
  
 
 
 
 
Subjects were injected with RZL -012 or vehicle perpendicularly (90 ) to the skin. An ice pack 
was placed on the injected area for pain relief immediately after injection. Subjects had to remain 
seated in the injection position for an additional 10 minutes after dosing . 
RZL -012-SMF -P2a-US-001 Results:  
AEs were closely followed up throughout the study to determine the  safety profile of RZL -012. 
Different scales were used to grade the severity degree of edema and erythema, pain, bruising 
and induration. Most of AEs were treatment related.  
The most commonly reported AEs were bruising, induration, edema,  pain and erythema  all of 
which were reported with a similar incidence in the RZL -[ADDRESS_484159] 24 hours of administration. The intensity then went from moderate to mild in the 
days following the RZL -012 injecti on and were completely resolved by 56 days after injection 
without any specific treatment or medication. Erythema, and bruising were not dose related and 
were mostly resolved at 14 days after injection. There were no clinically significant changes in 
vital signs, no deaths and no SAEs in any subjects . 
Based on the objective MRI, it can be concluded that the efficacy of RZL -012 in reducing SMF  
in this Phase 2a study was demonstrated. This is evident by [CONTACT_386327] (thickness) as we ll as volume.  The robustness of these results is supported by [CONTACT_386328], i.e., a volume reduction of -
22.2%±14.9 vs. Volume reduction of -10.6%±14.5 and -0.4%±13.[ADDRESS_484160] satisfaction. S ubjects that were treated with RZL -

Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484161] satisfaction. Placebo subjects did 
not demonstrate a satisfaction on Day 84 vs. baselin e. 
[IP_ADDRESS].5.  Protocol No. RZL -012-DD-P2bUS -001.4 Status: Completed  
Another study f or DD patients, a double -blind, randomized, multi -center, placebo -controlled 
phase 2b clinical trial for the evaluati on of efficacy and safety of RZL -012 in subjects having 
DD, is being conducted under IND 135762.  
The primary objective is to evaluate  of the efficacy of RZL -012 following injection into 
lipomas/nodules of DD subjects. Efficacy is determined by [CONTACT_386329]/nodule di mensions after treatment as compared to  baseline  assessments . 
The key secondary objective is  the assessment of lipoma/nodule associated pain using the 
Comparative Pain Scale. Safety is assessed by [CONTACT_386330] -from -
baseline values for vital signs, clinical laboratory and ECG.  An e xploratory objective  is to follow 
improvement  in Quality of Life by [CONTACT_386331] . 
A total of [ADDRESS_484162] been enrolled into the study. Subjects were  randomized in a 1:[ADDRESS_484163] 4 lipomas/nodules, preferably 6, and no more than 8, were  injected per subject. Dosing 
was determined  according to lipoma size, where the total injected dose did exceed 240  mg per 
patient (48 injections of 5mg/injection).  Table [ADDRESS_484164] 1 cm. Injections are given at 90° to the injected skin surface.  
Once the study ends and codes are opened, 84 days after dosing, placebo -treated subjects  will be 
offered the option of receiving treatment with RZL -012. Subjects who choose to receive 
treatment with RZL -012 will be followed for an additional 84 days.  Number of Subjects – 
Active /Placebo  20/18  
Lipoma/ Nodule size – 
diameter (cm)  1-1.9 2-3.9 4-5.9 6-7.9 8-10 
Total Dose of RZL -012 
in the RZL group  (mg)  10 20 40 50 60 
Number of Injections   2 4 8 10 12 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 38 of 72 CONFIDENTIAL  
 RZL -012-DD-P2b-US-001.4 Results  for the Double blind part : 
A total of [ADDRESS_484165], based on painful 
lipomas size.  
Change in Lipoma Height  
Dimensions of treated lipomas were measured at baseline visit prior to injection and at each of 
the follow up visits by [CONTACT_386332].  
Lipoma dimensions were compared between the active and placebo treatment groups on 2 levels 
– (1) on the patient level and (2) by [CONTACT_386333], i.e. comparison between all injected lipomas befor e 
and after injection.  
The Non -parametric Wilcoxon -Mann -Whitney Rank sum test for independent samples was 
applied for testing the statistical significance of the difference between study groups in percent 
reduction of lipoma/nodule height at day 84 after i njection vs. baseline per patient.  
The MMRM model (Mixed -effect model for repeated measures) was applied for analyzing the 
difference between the groups in percent reduction of lipoma/nodule height from baseline to day 
84. 
A total of 125 lipomas were measu red at baseline in the RZL -012-treatment group and 109 
lipomas in the placebo group in the double -blind phase of the study.  
The by -patient analysis demonstrated an average height reduction of 11.18%±22.70 (standard 
deviation) in the RZL -012 treated subjec ts vs. an average height reduction of 15.26%±21.05 in 
the placebo -treated subjects (P>0.05).  
The average height reduction change by [CONTACT_386334] a reduction of 
11.22%±33.77 in the RZL -012 treated group vs. 16.28%±29.60 in the placebo group  (P>0.05).  
Changes in lipoma dimensions using the analysis per lipoma demonstrate a similar trend, i.e., no 
statistically significant changes from baseline in lipoma height were found between active and 
placebo lipomas. The P value was calculated by a Mixe d model with repeated measure . 
More than 90% of injected lipomas contained fibrotic tissue and this was the hypothesis for not 
demonstrating an effect on lipoma size.  
Change in Lipoma Pain 
Pain of each injected lipoma was assessed by a blinded subject at baseline visit prior to injection 
and at each of the follow -up visits by [CONTACT_386335]. The comparative pain 
scale is a scale that contains 11 grades where 0 is categorized as ‘no pain’ and 10 is categorized 
as ‘extreme, non tolerable pa in’. 
Pain was compared between the RZL -012 and placebo treatment groups on 2 levels – (1) on the 
patient level and (2) by [CONTACT_386333], i.e. comparison between all injected lipomas before and after 
injection.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484166] for independent samples was 
applied for testing the statistical significance of the difference between study groups in percent 
reduction of lipoma/nodule pain at day [ADDRESS_484167] for independent samp les was applied for analyzing the difference between 
the groups in percent reduction of lipoma/nodule height from baseline to day 84.  
The MMRM model (Mixed -effect model for repeated measures) was applied for analyzing the 
difference between the groups in p ercent reduction of lipoma/nodule pain from baseline to day 
84. 
A total of 125 lipomas were assessed for pain in baseline in the RZL -012-treatment group and 
108 lipomas in the placebo group.  
The all-lipoma analysis demonstrated an average pain reduction o f 59.06%±40.41 in the RZL -
012 treated group vs. -37.50%±49.69.  The statistical significance tested by [CONTACT_386336] a p value of 0.079.  Calculation of statistical difference using t -test 
generated a  p value  of 0.0004.   
An additional analysis calculated the proportion of subjects with at least 40% reduction in pain in 
each treatment group. According to the medical literature, in patients wi th general chronic pain, a 
difference in pain intensity of >3 0% is considered a  clinically important improvement . 
It was calculated that 14 out of 20 patients (70%) in the RZL -012 treated -group vs. 8 out of 18 
patients (44%) in the placebo -treated group ha d more than 40% pain reduction. This supports the 
ability of RZL -012 in producing a clinical meaningful reduction in pain.     
No significant change in QOL was noted according to the completed questionnaire, possibly due 
to the relatively small number of l ipomas treated per patient.  
RZL -012-DD-P2b-US-001.6 Results for the open label extension phase:  
Nine (9) subjects treated with placebo in the double -blind phase of the study agreed to enter the 
open -label phase in which they were treated with RZL -012. A total of 65 painful lipomas were 
treated and followed up for pain reduction on Day 84, and 63 lipomas were followed up until 
Day 84 for change in dimensions.  
Study results demonstrated a reduction in lipoma height of ~20% on Day 84 vs. baseline.  Based 
on the per -patient analysis there was a mean reduction of -20.57±19.26% in lipoma height and 
based on the all treated lipomas analysis there was an average reduction of -21.12±29.69% in 
lipoma height.  
No serious adverse events were reported in the s tudy.  
[IP_ADDRESS].6.  Protocol No. RZL -012-hADMEC14 -001 Status: completed  
A Phase 1 study which  assessed the absorption, metabolism, excretion  (ADME) , and mass 
balance of 72.9mg subcutaneous injection of [14c] -RZL -012 in 6 healthy male subjects.  The 
study was conducted u nder IND 135762.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 40 of 72 CONFIDENTIAL  
 The study results showed a total recovery of the administered radioactivity was approximately 
85.37% (by 2 weeks after dosing), of which 2.542% and 82.83% were recovered in urine and 
feces, respectively, indicating that hepatobiliary excr etion into the feces is the main elimination 
route for [14C] -RZL -012-realated material in humans, with renal elimination playing a 
secondary role. The PK profile of the [14C] -RZL -012 was similar to the profile shown in 
previous clinical studies.  
[14C] -RZL -012-injected radioactivity is rapi[INVESTIGATOR_24584] (T max = 2hr) and widely distributed 
across body tissues. This is followed by a slow elimination stage with ~85% of the drug being 
excreted within 2 weeks. In addition, study demonstrated low/no radioactivity i s remaining at 
one month post dose of [14C] -RZL -012 compound . Therefore, no accumulation is expected in 
case of once monthly or less frequent dosing regimen.  
 
[IP_ADDRESS].7.  Protocol No. RZL -012-SMF -P2bUS -001.2 Status: Ongoing  
A double blind, randomized, three -arm, placebo -controlled Phase 2b study to evaluate the 
efficacy and safety of RZL -012 in subjects seeking submental fat reduction , is being conducted 
under IND 154260.  
The primary objective is to the efficacy of RZL -012 versus placebo on submental fa t (SMF) 
reduction measured on Day 84 versus baseline using the Clinician Assessment Tool (C -CAT) . 
The secondary objectives are:  
• To determine the efficacy of RZL -[ADDRESS_484168] Self -Chin Assessment Tool (S -CAT);  
• To assess the reduction in SMF on Day 84 versus baseline using the caliper measured 
submental thickness and magnetic resonance imaging (MRI);  
• To assess the safety of RZL -[ADDRESS_484169] wil l be randomized to either active treatment (high or low dose RZL -012) or 
placebo at a ratio of 1:1:1 per group and receive one of the following:  
• low dose (concentration of injected solution 34 mg/mL RZL -012) of 5.1 mg/0.15 
mL/injection point that results i n a dose/volume of 183.6mg/5.4 mL RZL -012, 
• high dose (concentration of injected solution 50 mg/mL RZL -012) of 7.5 mg/0.15 
mL/injection point that results in a maximum total dose/volume of 270 mg/5.4 mL RZL -
012, 
• placebo of 0.15 mL/injection point that resul ts in a total maximum volume of 4.8±0.6 
mL. 
The injection pattern will be based on a submental area shaped grid in which the distance 
between rows and columns will be 1 cm, as seen in the figure below. The Investigator will 
choose 32±4 sequential points on  the grid that will mark the injected area according to SMF 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 41 of 72 CONFIDENTIAL  
 fullness and convexity. The treatment area boundary: superiorly by a line 1 cm inferior to the 
mandibular margin, laterally by [CONTACT_113388], and inferiorly by [CONTACT_386337] . 
 
Results of study RZL -012-SMF -P2bUS -001.2:  
The study is blinded and still on -going.  
As of [ADDRESS_484170] been enrolled into the study out of 155 
planned subjects. Safety data that was collected for these subjects.  
Overall, 97 A Es were reported in 32 out of 40 subjects (80.0%) (based on data entry as of 19 
September 2021  as part of safety committee ).  Thirty -one subjects (77.5%) experienced AEs that 
were considered as related to study drug, 9 (22.5%) experienced AEs that were co nsidered 
“Related to skin irritancy” and 30 (75.0%) experienced AEs that were considered “Related to 
injection procedure” as determined by [CONTACT_737].  
There were 5 events that were assessed as severe.  Except the event of oedema, of which the 
outcom e was not available at the time of report, all of them recovered within 28 days (1/40 = 
2.5% may not have been recovered beyond 28 days).  
Among [ADDRESS_484171] common events based on preferred term (PT) were oedema (20 events, 
20 subjects), pain (15 even ts, 15 subjects), contusion (13 events, 13 subjects), hypoaesthesia (11 
events, 11 subjects), swelling (11 events, 9 subjects), pruritus (4 events, 4 subjects), and 
ecchymosis (3 events, 3 subjects). Out of 97 AEs, 74 AEs (76.3%) were mild, 18 AEs (18.6%) 
were moderate, and 5 AEs (5.2%) were severe. Eighty AEs (82.5%) were considered as related. 
Eighty AEs (82.4%) were reported as recovered/resolved or recovering/resolving at the time of 
the report. No AEs were considered severe or life -threatening or resul ted in death. No AEs were 
serious or resulted in discontinuation from the study.  
There were 306 findings  of abnorm al laboratory values reported in 39 subjects after dosing . The 
abnormal laboratory values observed ≥ 10% ( ≥ 4 subjects) during the visit is as below.  After 
dosing at Day 1, more than 10 subjects ( ≥ 25%) reported D -dimer, high, glucose, high, and LDH, 
high, whereas no subjects experienced elevated fibrinogen activity, abnormal INR, or abnormal 
APTT and one subj ect experienced slightly longer prothrombin time (12.4 sec).  The ratio of 
number of such subjects who experienced abnormal increase at Day 1 decreased over visits and 
became closer to the number at screening by [CONTACT_2006] 28 except blood glucose. Of note, glucos e was 
not necessarily measured at fasting condition.  

Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 42 of 72 CONFIDENTIAL  
 Two (2) out of the forty injected subjects demonstrated an increase of [ADDRESS_484172]. The other reported out -of-normal -range levels of ALT (for 
additional 5 subjects) were slightly elevated above normal range or were higher in screening and 
remained higher after injection.   None of the reported subjects had elevation  of 2xULN in AST 
values. Furthermore, there are no subjects with total serum bilirubin  values or alkaline 
phosphatase above the normal range.  
2.0 STUDY OBJECTIVES  
2.1 Study Objectives  
The objective of the study is to assess the safety and efficacy of RZL -012 injec tions  into the 
flank  area. 
2.1.1 Primary Objective  
The primary objective of this study is: 
• To assess safety and tolerability of a single RZL -012 injection session into the flank . 
2.1.2 Secondary Objective  
The secondary objective s are: 
• To evaluate the efficacy of RZL -012 treatment versus placebo treatment on fat reduction in 
the flanks  
• To assess the safety of a second dose of RZL -[ADDRESS_484173] -treatment follow -up period.  At the baseline visit, each flank 
(right and left) of each study par ticipant will be randomized into either the active RZL -012 
treatment group or the placebo group and each flank will be treated with multiple injections  in a 
single injection session of RZL -012 or placebo. Subjects will be followed up for 12 weeks after 
the single treatment session.  
Upon completion of the double -blind phase of the study and the opening of codes , subjects will 
be offered RZL -012 open -label treatment in the flank previously treated with placebo.  
Consenting subjects will be followed for safet y and efficacy for an additional 12 weeks.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 43 of 72 CONFIDENTIAL  
 2.3 Study Endpoints  
2.3.1 Primary Endpoint  
The primary endpoint of this study is : 
• To evaluate safety following a single injection session of RZL -[ADDRESS_484174] (highest previous dose, 
270mg/subject). Lab tests, ECG, skin irritancy and AEs related to the injection procedure will 
be evaluated for frequency, severity and duration up to 84 days after dosing.  
2.3.2 Secondary  Endpoints  
The seconda ry endpoints of this study are as follows:  
• Comparison of the proportion of flanks having an improvement as indicated by a score of 0 to 
6 according to the Physician Global Assessment Scale (GAIS) in RZL -012 vs placebo treated 
flanks.  
• Comparison of the proportion of subjects who are satisfied with treatment results as indicated 
by a yes/no satisfaction questionnaire in RZL -012 treated flanks  vs placebo treated flanks.   
 
• Mean r eduction in volume at [ADDRESS_484175] treatment vs. baseline for each of the treated 
flanks, as measured by 3D photographs . 
• Ability of blinded reviewers to correctly identify, per patient, the flank treated with test 
compo und (active) vs the flank treated with vehicle (placebo). Success will be defined as at 
least 70% correct identification vs the expected 50% correct identification based on random 
guessing  
• .  
• Evaluate safety following a second  dose of RZL -012 based on AEs,  laboratory tests, ECG, 
skin irritancy.  
• Characterization of RZL -012 pharmacokinetic (PK) profile .  
 
2.3.3 Randomization/Assignment to Study Drug  
Each flank (right and left) of each study participant (12 subjects) will be randomized into either 
the active RZL -012 treatment group or the placebo group and each flank will be treated with 
multiple injections in a single injection session of RZL -012 or placebo.  Upon completion of the 
double -blind phase of the study, and the opening of codes , subjects will be offered RZL -012 
open -label  treatment in the flank previously treated with placebo.   
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484176]  and Dosing  
RZL -012 is a novel synthetic molecule  provided as a sterile liquid solution suitable for injecti on. 
At the start of the double -blind, placebo -controlled phase of the trial each flank (right and left) of 
each study participant will be randomized into either the active RZL -012 treatment group or the 
placebo group and each flank will be treated with mul tiple injections in a single injection session 
in accordance with Table 4 below:  
Table 4 Dosing Regimen  
 
 
 
 
 
 
 
Upon completion of the double -blind phase of the study and the opening of codes , subjects will 
be offered RZL -012 open -label treatment in the flank previously treated with placebo in the same 
manner as described in Table 4 above .   
RZL -012/placebo  injections –Treatment will cover the area of each random ized flank. A surface 
area of 15cm x6 cm will be chosen for treatment as per the temporary tattoo grid shown below.  
Flanks will be injected with RZL -012/placebo with the needle pointing perpendicular (90°) to 
skin surface. An ice pack will be placed on th e injected area for pain relief immediately after 
injections are completed. Subjects will remain in injection position for an additional 10 minutes 
after dosing.  
The injection pattern will be based on the following grid in which the distance between rows a nd 
columns will be 1.5 cm, as seen below.  
Injections will be conducted with a 27G needle (1 inch needle length) in order to allow direct 
injections into the depth of fat tissue.   RZL -012 (50mg/mL  
DP injectable solution)  Placebo (Injectable sterile solution)  
Randomized Right or 
left flank  12 12 
Single Treatment  55 injections at 
7.5mg/0.15mL per 
each injection point –
A total of 412.5 
mg/8.25 mL total dose 
per flank  55 injections at 0.15mL per each 
injection point –A total volume of 
8.25 mL total dose per flank   
* 55 injections are the maximum number of injections. In case of smaller flank s, the 
number of injections may be lower.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 45 of 72 CONFIDENTIAL  
 Figure 7 Scheme of Injection Pattern Grid  
 
 
 
 
 
 
 
2.4.2 Dose Rationale  
The maximal dose of RZL -012 administered to subjects to date was 270  mg via 36 injections of 
7.5 mg/0.[ADDRESS_484177] and the amount given per injection site  were well tolerated and not associated 
with any significant safety issues. To cover the flank area in the current study, the maximal dose 
will be increased to 412.5  mg per session via 55 injections of 7.5  mg/0.15  mL per injection with 
the distance between  injection sites of 1.5  cm. Subjects who receive a second  RZL -012 dose will 
receive a maximal RZL -012 dose of 412.5X2=825  mg across 2 dosing sessions, at a 3 -month 
interval between injection sessions.     
The maximal dose of RZL -012 administered to non -rodents (pi[INVESTIGATOR_14107]) to date was 1,000  mg via 40 
injections of 25  mg/0.5  mL per injection, with the distance between injection sites being 1 -2 cm. 
This dose was given monthly at 4 injection sessions per pig and was well tolerated without any 
significant systemic or local side effects. Dosing pi[INVESTIGATOR_22736] 4 °x°1,000mg is equivalent to about 
4°x°900 mg in humans, based on body surface area calculations. These preclinical studies 
provide a good margin vs anticipated human dosing both in terms of the to tal dose, dosing 
frequency (once monthly in pi[INVESTIGATOR_386299] 3 months in humans) and amount per injection site 
(25°mg in pi[INVESTIGATOR_386300] 7.5 °mg in humans) . 
2.4.3 Serious Adverse Events Considered Related to the Investigational Drug  
AEs and serious adverse events (SAEs) wil l be monitored throughout the study.  
Study discontinuation is to be considered by [CONTACT_386338] (CRFs).  
SAEs are considered to be related to the study drug.  
Subjects experiencing an SAEs will be followed for their skin condition.  
SAE should be reported within 24 hours to the medical monitor.  

Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 46 of 72 CONFIDENTIAL  
 The study may also be prematurely terminated in any of the following cases:  
• Recurring serious or severe Adverse Drug Reaction (ADR) clinically evaluated by [CONTACT_976] [INVESTIGATOR_296284].  
• A decision made by [CONTACT_2728]/medical monitor and/or IRBEC and /or local regulatory 
agency to terminate the study  
2.5 Concomitant Medications  
2.5.1 Prior and Concomitant Medications  
Prior medications are defined as medications that were taken within 30 days prior to initial 
dosing with study drug.  
Concomitant medications are de fined as medications taken any time after the start of dosing until 
discharge assessments. All concomitant medication, including blood and blood products, dietary 
supplements, and non -prescription drugs , will be listed at screening/baseline. Each entry wil l 
include the treatment's start date, treatment name (Generic), reason for use, dosing regimen (dose 
and frequency of use), route of administration, and stop date (if applicable). The clinical 
significance of the medication use will be decided by [CONTACT_8647]. Study subjects will be 
routinely questioned for changes in the administration of concomitant medication during the trial 
and changes should be updated from medical records as well . 
3.[ADDRESS_484178] meet all of the following criteria:  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484179] between the ages of 18 and 65 years, inclusive.  
2. Has body mass index (BMI)  BMI of ≥ 22 and < 30.  
3. Has clearly visible and palpable fat in the flanks  
4. Has symmetrical appearance of right and left flanks  
5. Agrees to maintain weight (i.e., within 5% of body weight)  by [CONTACT_386339]. 
6. Agree to avoid exposure of the treated area to sun for at least 1 month after each treatment 
session.  
7. If female, is not pregnant or breastfeeding based on the following:  
a. agree to the use of highly effective contraceptive methods  for at least [ADDRESS_484180] at screening and baseline; or  
b. is of nonchildbearing potential defined as clinically infertile as the result of surgical 
sterilization (hysterectomy, bilater al tubal ligation, and/or bilateral oophorectomy); or   
c. is confirmed postmenopausal status (defined as either having amenorrhea for ≥ 12 
consecutive months without another cause , having documented serum follicle -
stimulating hormone (FSH) level > 40 mIU/mL, or having another documented medical 
condition (e .g., was born without a uterus) ) 
NOTE: The following are considered highly effective contraceptive methods: hormonal 
oral contraceptives, injectables, and patches; intrauterine devices; double -barrier method s 
(synthetic condom, diaphragm, or cervical cap used with spermicidal foam, cream, or 
gel); and male partner sterilization.  
8. If male (with or without vasectomy), agree to the use of highly effective contraceptive 
methods, e.g. condom, from study baseline un til [ADDRESS_484181] day of study drug.  
9. Is willing to avoid strenuous exercise for seven (7) days post treatment.  
10. Is able to adhere to the visit schedule and protocol requirements and be available to complete 
the study.  
11. Is willing and able to sign an Institutional Review Board (IRB) approved informed consent 
form (ICF) indicating that they are aware of the investigational nature of the study.  
3.[ADDRESS_484182] NOT  meet any of the following Exclusion criteria to be eligible for enrollment:  
1. Is unable to tolerate subcutaneous injections.  
2. Has dysfunctional gallbladder activity (e.g., underwent cholecystectomy or cholecystitis).  
3. Has any uncontrolled systemic disease tha t is not stabilized (i.e., cardiovascular disease, 
mental illness).  
4. Has used anticoagulation therapi[INVESTIGATOR_113378] (i.e., aspi[INVESTIGATOR_248], 
ibuprofen, vitamins, and herbal preparations) for seven (7) days prior to treatment.  
5. Has medicatio n or a history of coagulopathy.  
6. Has a history or family history of venous thrombotic disease.  
7. Has a known sensitivity to cold or has any condition with a known response to cold exposure 
that limits blood flow to the skin, such as cold urticaria, Raynaud's disease, or chilblains 
(pernio).  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 48 of 72 CONFIDENTIAL  
 8. Had a non -invasive fat reduction and/or body contouring procedure in the flanks within the 
past 12 months.  
9. Has any scars, unshaven hair, tattoos, on or near the proposed treatment area.  
10. Has significant history or current ev idence of a medical, psychological or other disorder that, 
in the Investigator’s opi[INVESTIGATOR_1649], would preclude enrollment in the study.  
11. Has an active dermatitis or open wound in the proposed treatment area.  
12. Abnormal coagulation profile including: activated parti al thromboplastin time (aPTT) > 
ULN, international normalized ratio (INR)  > ULN reference range (>  1.3), prothrombin time 
(PT) > ULN.  
13. Has an active bacterial, fungal, or viral infection in the proposed treatment area.  
14. Has known allergic reactions to any in jectables.  
15. Has been treated chronically in the past three (3) months prior to study entry with systemic 
steroids or immunosuppressive drugs.  
16. Has been treated chronically at least one (1) week prior to study entry with non -steroidal 
anti-inflammatory drugs (NSAIDs).  
17. Current participation or participation within three (3) months prior to the start of this study in 
a drug or other investigational research study.  
 
3.[ADDRESS_484183] rather 
than the subjects’ name, personal identification numbers, and/or addresses to protect the 
subject’s identity. The code numbers and initials will be used in lieu of the subject’s name [CONTACT_386360]/or other trial related data.  
3.[ADDRESS_484184] voluntarily confirms their willingness  to pa rticipate in the trial. The 
Investigator or  his/her approved designee must explain the nature of the study protocol and 
associated risks to the potential study participant. The potential participant must be allowed to 
review the study information and to ask questions before being asked to sign the Informed 
Consent Form (ICF). Written informed consent must be provided by [CONTACT_386340] -related procedures. The 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484185]’s medical record.  
The ICF approved by [CONTACT_1201]/EC will contain a description of the study’s p urpose, purpose, 
procedures, inconveniences and potential risks , and anticipated benefits.  Prior to participation in 
the trial, the sub ject will receive a copy of the signed and dated written ICF. During participation 
in the trial, the subject will receive a copy  of the signed and dated consent form updates and a 
copy of any amendments to the ICF provided to the subjects.  
After written informed consent is obtained, the subject will be assigned a screening number and 
will undergo the designated screening procedures listed in Appendix A . The Investigator, sub -
investigator or delegate will assess the results o f these screening evaluations to determine 
eligibility for entry into the study according to the inclusion/exclusion criteria listed in Section 
3.0. 
4.2 Complete Physical Examination  
The Investigator  (or medically qualified nominee)  will perform a complete physical exam  at 
screening  and on [ADDRESS_484186]’s medical history should be fully 
documented to  confirm eli gibility. Medical history must include, but not limited to, past and 
present medical conditions, concomitant non -drug treatments, and hypersensi tivity to drugs . 
4.4 Vital Signs  
Vital signs ( systolic and diastolic sitting position blood pressure, pu lse rate, respi[INVESTIGATOR_697], and 
body oral temperature ) are to be obtained at screeni ng to ensure c ompliance . 
Additional vital sign measurements to assess subject’s safety will be performed at baseline (Day 
0) prior to treatment  Week [ADDRESS_484187] is to be obtained at screening to ensure compliance.  ECG  will be done in triplicates.  
Additional ECG will be performed on Week 1, Week 4 and Week 12  visit.  
4.6 Height and Weight  
Height will be reported in centimeters at screening.  B ody weight will be reported in kilograms 
(kg) at screening.  
Weight measurement will be performed at screening to determine the BMI value. An additional 
weight measurement will be performed at baseline and at study visits on Week 4, Week 8  and 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 50 of 72 CONFIDENTIAL  
 Week 12 visit to verify no significant changes in weight  throughout the assessment of flank  
changes during the study.  
4.7 Pharmacokinetics  
Samples for t esting of RZL -012 Pharmacokinetics will be taken from 6 subjects at the baseline 
visit till the following day (Day 0 -1).  Subjects will stay in a hotel nearby [CONTACT_386341] .  Blood 
samples (10 mL blood per sample in K 2EDTA vials, 100 mL/subject/24h) will be taken after 
study injection at the given time points: 0, 30, 60 min, 2h, 3h, 4h, 6h, 8h, 24h  and 30h .  Whole 
blood samples (10 mL x 10 time points) will be store d on an ice block or wet ice until 
centrifuged.  Samples will be placed in the centrifuge and spin cycle started within 60 minutes of 
collection.  Samples wi ll be centrifuged at 1200  g in 4 °C for 10 minutes.  Plasma will be 
removed and placed in aliquots (4 aliquots of 1  mL each) within 20 minutes of centrifugation and 
flash frozen on dry ice.  Processed samples will be placed in frozen ( -60 to -90 °C) storag e.  
Determination of RZL -012 in K 2EDTA human plasma a validated method of Liquid 
Chromatography -Tandem Mass Spectrometry will be conducted and analyzed  further. Samples 
(2 aliquots/subject/time point) will be sent frozen on dry ice and 2 aliquots will be r etained for 
possible future analysis  
4.8 Clinical Laboratory Evaluations  – Hematology and Serum Chemistry  
Screening blood samples and uri ne specimens  for laboratory evaluation will be collected at 
screening  to confirm eligibility. Additional blood samples will  be collected at Week 1 , Week 4  
and Week 12  study visits for an assessment of hematology and serum chemistry . 
If there are clinically significant alerts obtained at any visit , an unscheduled visit will be added 
for additional blood sampling . 
4.8.1 Hematology  
Complete blood cell count (CBC) will include a standard red blood cell ( RBC ), white blood cell 
(WBC ) with differential, hemoglobin, hematocrit, platelets, D-dimer , Fibrinogen and coagulation 
(International normalized ratio [INR], partial throm boplastin time [PTT] and prothrombin time 
[PT]).  
4.8.2 Serum Chemistry  
Comprehensive metabolic panel will include serum alkaline phosphatase  (ALP) , alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), glucose, calcium, globulin 
(calculated), phosphoru s, chloride, sodium, potassium, blood urea nitrogen (BUN) /creatinine  
ratio (calculated) , creatinine with GFR estimated,  total bilirubin, albumin,  albumin/glo bulin 
ratio (calculated),  total protein, amylase, bicarbonate/carbon dioxide (CO 2), uric acid,  gamma-
glutamyl trans ferase (GGT),  and lactate dehydrogenase (LDH).  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 51 of 72 CONFIDENTIAL  
 4.8.3 Pregnancy Tests  
A serum (ß -hCG ) pregnancy test will be administered to females of childbearing potential at 
screening and a urine pregnancy test will be administered at baseline  prior to dosing . Additional 
serum pregnancy tests will be done at any time during the study (up to 12 weeks ), if pregnancy is 
suspected.  
4.9 2-D and 3 -D Standardized Photography  
Standardized photography (2 -dimensional  and 3 - dimensional ) of the flanks area  will be 
conducted at screening in order to establish a baseline value for assessment of treatment efficacy.  
Additional photography will be conducted on week [ADDRESS_484188] was treat ed with RZL -012 or placebo by [CONTACT_386342] 12 weeks after treatment.  
The 3D photos will be used to compare the images of each treated flank in screening vs. 12 
weeks visit and to calculate the vo lumetric change before and after treatment.  
4.10 Physician Global Assessment Improvement Scale (GAIS)  
Investigator will assess the improvement of each flank (right and left)  following treatment by 
[CONTACT_386343] 4, 8 and 12 visits.  
At each study visit, the Investigator will assess the improvement degree based on the following 
scale:  
Grade  Description  
0 Completely clear  No evidence of fat; 100% improvement  
[ADDRESS_484189] clear  Very significant clearance (≥90% to <100%); only 
trace remain  
2 Marked 
improvement  Significant improvement (≥75% to <90%); some 
evidence of  fat remains  
3 Moderate 
improvement  Intermediate between slight and marked improvement 
(≥50% to <75%)  
4 Slight 
improvement  Some improvement (≥25% to <50%); significance 
evidence of fat remains  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 52 of 72 CONFIDENTIAL  
 5 No change  Fat has not changed from baseline condition (±25%)  
6 Worse  Fat is worse than at baseline evaluation by ≥25% or 
more  
 
 
4.[ADDRESS_484190]’s Sati sfaction Questionnaire  
Subject’s satisfaction questionnaire (yes/no questions) will be conducted by [CONTACT_386344] (right and left) at study visits on Week [ADDRESS_484191]’s 
satisfaction with their flanks after treat ment. Subjects will be asked with the following question s 
and answers for each question will be Yes/No : 
For the right/left flank, are you satisfied with the treatment ? 
Would you have the treatment again in the right/left flank?  
Would you recommend the treatment to a friend?  
4.[ADDRESS_484192] questioning.  
5.0 SAFETY ASSESSMENTS  
5.1 Collection of Adverse Events Data  
Data regarding treatment -emergent AEs (TEAEs) will be collected in this study.  TEAEs are 
events that are not present at baseline, or if present at baseline, have worsened in severity. AEs 
will be assessed while the subjects are in the study. AEs assessed by [CONTACT_386345] “ongoing” at discharge will be monitored by [CONTACT_386346] “lost to follow -up”. 
Any AEs reported by [CONTACT_386347]/her designee will be recorded 
on the eCRF regardless of the Investigator opi[INVESTIGATOR_17963]. The fo llowing information will 
be recorded for each AE: description of the event, date and time of onset, date and time of 
resolution, severity, causal relationship to study drug, outcome, action taken with the study drug 
and any treatment given.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 53 of 72 CONFIDENTIAL  
 The AEs reporte d during the trial will be graded, documented, and assessed in regards to their 
clinical significance and relation to study drug. Treatment area evaluation includes, but is not 
limited to, evaluation of edema, pain, bruising, erythema, induration, numbness , paresthesia, 
tenderness, and pruritus . 
All abnormal changes from baseline will be collected, graded with regards to severity or clinical 
significance, assessed for causal relationship and recorded on the eCRF.  
5.2 Complete or Targeted Physical Examination  
The Investigator will perform a complete PE at screening  and on 12 weeks visit. 
5.3 Vital Signs  
Vital signs (systolic and diastolic sitting position blood pressure, pulse rate, respi[INVESTIGATOR_697], and 
body oral temperature) are to be obtained at screening to ensure compliance.  
Additional vital sign measurements to assess subject’s safety will be performed at baseline (Day 
0) prior to treatment  and after treatment , and during study visits on Week 1, 4, 8 and 12 . 
6.0 PHARMACOKINETICS  
PK measures will be  assessed during this study  for 6 of 12 subjects in the study . Description of 
the procedure is detailed in section 4.7.   
7.0 EFFICACY  
Efficacy measures include the following:  
• Efficacy of RZL -012 versus  placebo on fat reduction measured on 12 weeks visit  versus  
baseline using the physician’s GAIS  and blinded committee images identification of 
flanks before and after treatment for each of the subject’s flanks . 
• Assessment of the reduction in flanks volume  on 12 weeks visit  compared to baseline 
using 3D photos .  
• Assessment of flanks  improvem ent using  the subject’s satisfaction questionnaire .  
8.0 STUDY VISITS AND PROCEDURES  
Refer to  Appendix A  for the Schedule of Study Procedures.  
8.1 Screening (Days -28 to -1) 
The Investigator or his/her approved designee must explain the nature of the study protocol and 
associated risks to the potential study participant. The potential participant must be allowed to 
review the study information and to ask questions before being asked to sign the Informed 
Consent Form (ICF). Written informed conse nt must be provided by [CONTACT_386340] -related procedures. The 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484193]’s medical record.  
After written informed consent is obtained, the subject will be assigned a screening number and 
will undergo the designated screening procedures listed in Appendix A . The Investigator, sub -
investigator or delegate will assess t he results of these screening evaluations to determine 
eligibility for entry into the study according to the inclusion/exclusion criteria listed in Section 
3.0. 
Screening evaluations may be performed up to  [ADDRESS_484194] 1 day  prior to Day 0. 
The following study evaluations and procedures are required to determine eligibility:  
• Obtain and record a medical history, including demographics, prior medications, and 
concomitant medications.  
• Complete physical examination  
• Vital signs  
• ECG  
• Height and weight measurements  
• Blood and serum samples for the following laboratory evaluations:  
o Hematology  
o Serum chemistry  
o Coagulation  
o Pregnancy (if applicable)  
• 2D photography  
• 3D photography  
Subjects may be re -screened if they were screened and not dosed within 28 days. The following 
procedures will be performed: vital signs  and wei ght measurements.  
8.2 Baseline Evaluations (Day  0) 
Following the screening visit, subjects determined to be eligible for participation in the study 
will undergo baseline assessments . Baseline evaluations will be performed upon admission to the 
clinical research unit on Day  0. 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 55 of 72 CONFIDENTIAL  
 Baseline assessments inclu de the following:  
• Confirm eligibilit y  
• Vital signs  
• Weight me asurement  
• Concomitant medications  
• Urine pregnancy tes t (if applicable)  
Once subjects are confirmed to be eligible, each of the flanks will  randomized to one of the 
treatment groups based on the randomization schedule.  
8.3 Study Randomization  
Each left and right f lank will be  randomized to each treatment  group accor ding to a predefined 
randomization scheme in a ratio of 1:[ADDRESS_484195] eligibility is confirmed and immediately prior to injection treatment . 
The Investigator , clinical staff and the subjects will be blinded to treatment group.  
8.4 Pre-dose Evaluation (Day 0)  
Pre-dose assessments on Da y 0 include the following:  
• Vital signs  
• First blood sample for PK  for 6 out of 12 subjects  
8.5 Drug Administration  
RZL -012 and placebo will be supplied as a single treatment in multiple sites of injection (55 
injections ). The injection dosing regimen and tech nique is crucial for the therapy safety.  
The following procedures prior to injection into the flanks  will be applied:  
1. The flank area  will be cleaned with an appropriate topi[INVESTIGATOR_113380].  
2. Ice/cold pack or topi[INVESTIGATOR_113381] (i.e., lidocaine cr eam) may be used prior to drug 
administration to enhance subject’s comfort.  
3. Injection grid pattern will be applied by [CONTACT_113390], dry skin, 
with the printed grid pattern facing the skin. The grid paper backing will be thoroughl y 
wetted with a cotton pa d soaked with sterile wate r. After 15 seconds, the grid  cover will 
be peeled off.  
4. An area of 55 adjacent injection points will be determined following the Investigator’s 
evaluation.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 56 of 72 CONFIDENTIAL  
 5. Syringes will be filled with 1 mL RZL -012 or plac ebo and the number of syringes will be 
compatible with the total volume of injection. Up to 9 syringes for a total volume of 8.25 
mL will be used  for each of the flanks . 
6. All injections will be administered perpendicularly in 90  degrees, using a 1 mL Luer -lock 
syringe and a 27G x 1” needle, respectively.  
7. The hole of the needle should be po inting into the fat layer and the injection direction 
should be towards the earth. An attempt to pull the plunge r should be made prior to 
injecting to ensure no blood is co ming out. If so, the plunger should be pu shed down to 
inject 0.15 ml the medicine. The formulation is viscous; therefore, resistance is expected 
during injection.  
8. Immediately following completion of the inje ctions, an ice/cold pack will be applied for 
imme diate pain relief. It will be held b y the subject for at least two (2) minutes.  
9. The Investigator will record the number of injections administered for each su bject.  
The injection pattern used will be based on the flanks area , where distance between injecti on 
rows will be [ADDRESS_484196] : 
• RZL -012 will be provided in vials of 240 mg/4.8 mL (50 mg/mL)  
 
Treatment with placebo will be conducted in the same manner as above.  
 
The calendar date and [ADDRESS_484197]-dose Evaluations (Day 0) and PK blood samples  
Post-dose assessments on Day 0 include the followin g: 
• Vital sig ns 
• Concomitant medication  
• AEs 
Following completion of injection treatment, an ice /cold  pack will be placed on the injected area 
for pain relief . Subjects will remain in the injection position for an additional ten (10) minutes 
after injections.  Six s ubjects will remain in the clinic up for [ADDRESS_484198] dosing and AE s assessments. Additional blood 
samples for PK will be collected at: 2h, 3h, 4h, [ADDRESS_484199] injection for medical supervisions and AEs 
assessment.   
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 57 of 72 CONFIDENTIAL  
 8.7 Study Visits  (Day 1, Week 1, 4, 8, and 12 ) 
Subjects will return to the cl inical site for study visits on Day 1 *,Week 1, 4 8 and 12 visits . Study 
visit assessments include the following:  
• Vital signs  
• Concomitant medication  
• AEs 
• Weight measurement  
• Clinical laboratory tests (Weeks  1, 4, 12) 
• Serum pregnancy test ( in case  pregnancy is suspected)  
• ECG ( Weeks 1, 4, 12 ) 
• Physician’s GAIS  (Weeks  4, 8, 12) 
• 2D and 3D  Photography  
• Subject’s satisfaction questionnaire ( Weeks 4,8, 12 ) 
• Blinded committee to identify which of the flanks was treated with placebo and which of 
the flanks was treated with RZL -012 (Week 12 ) 
 
*Blood sampling for PK is only relevant for [ADDRESS_484200] will return for an 
unscheduled visit and a repeat of hematology and serum chemistry.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 58 of 72 CONFIDENTIAL  
 8.8 Final Visit  (Week 12 ) 
Final s tudy visit assessments include the following:  
• Vital signs  
• ECG  
• Physical Exam  
• Concomitant medication  
• AEs 
• Clinical laboratory tests  (including serum pregnancy test, in case  pregnancy is suspected)  
• Weight measurement  
• 2D  and 3D Photography  
• Physician GAIS  and physician assessment  
• Subject’s satisfaction questionnaire  
• Blinded committee identification for treated  flanks  
8.9 Open -Label Phase  of the Study : 
Upon completion of the double -blind phase of the study and the opening of codes , subjects will 
be offered RZL -[ADDRESS_484201] following RZL -012 injection to the placebo 
treated flank  (there will be no screening visit in the open label part) : 
• Week 1 visit – vital signs, concomitant medication, ECG, labs, 2D and 3D photos, AEs.  
• Week 4 visit – vitals signs, concomit ant medication ,ECG, weight, labs, 2D and 3D 
photos, physician GAIS, subject’s satisfaction questionnaire, AEs  
• Week [ADDRESS_484202]’s satisfaction questionnaire, AEs  
• Week 12  visit – vitals signs, concomitant medication , physical examination, ECG, 
weight, labs, 2D and 3D photos, physician GAIS, subject’s satisfaction questionnaire, 
AEs 
 
9.[ADDRESS_484203] who signed informed consent 
ceases participation in this study, regardless of circumstances, prior to completion of the 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 59 of 72 CONFIDENTIAL  
 protocol. Subjects can be prematurely discontinued from the study for one of the following 
reasons:  
• Failure to meet inclusi on/exclusion criteria before receiving first dose of study drug has 
been administered  
• Death  
• Significant safety event that in the opi[INVESTIGATOR_24596] . 
Raziel will attempt to follow up all subjects for safety.  
• Lost to follow -up after every attempt has been made to contact [CONTACT_423], including 
sending a registered letter  
• Subject withdraws consent  
The Principal Investigator [INVESTIGATOR_74118]/Ethics Committee (IRB/EC) 
reserve the right to prematurely terminate the study in the interest of subject safety and welfare. 
The Sponsor reserves the right to prematurely terminate the study at any time for administrative 
reasons.  
10.[ADDRESS_484204] SPECIFICATIONS  
10.1 Description  
RZL -012 is a novel synthetic molecule (termed RZL -012) that can help reduce fat content 
following its injection into the subcutaneous fat . Chemically, RZL -012 is 5-(3,6-dibromo -9H-
carbazol -9-yl)-N,N,N -trimethylpentan -1-aminium chloride. RZL -[ADDRESS_484205] is > 97% pure.  
RZL -[ADDRESS_484206] was manufactured in Patheon (Italy) and packed and labeled at ThermoFischer, 
[LOCATION_003]. The drug product is provided in vials of 240  mg/4.8  mL (50 mg/mL).  
The active ingr edient and formulation manufacturing and packing were in accordance with 
cGMPs.  
RZL -012 will be provided in strength of 240 mg/4.8 mL (50 mg/mL).  
The placebo is a ready to use liquid to be injected into the subcutaneous fat, supplied in a 2 vials 
kit. Each  vehicle vial contains 4.8 mL solution volume.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 60 of 72 CONFIDENTIAL  
 10.3 Receipt, Storage and Stability of RZL -012 
The RZL -012 kit and placebo vehicle will be stored in the site at monitor ed room temperature 
conditions ( 15 - 30 degrees Celsius) protected from light.  
Drug product st ability has successfully reached three (3) years. Site inventory will be managed 
by [CONTACT_386348]. Suit ability of the product’s expi[INVESTIGATOR_386308] (FIFO) principals.  
10.[ADDRESS_484207] be kept and handled at room temperature . The vials should be 
manually shaken prior to injection.  
1 mL Luer -lock syringes with RZL -012 solution should be filled with 27 G 1”  sterile needle for 
a maximal dose of 412.5mg . Two vials will be used for each subject. Breached vials will not be 
used for another subject. Each vial must be placed back into the container. All open vials will be 
kept until the end of study when  the Sponsor will determine if study drug should be returned or 
destroyed.  
10.[ADDRESS_484208] was manufactured in Patheon (Italy) and packed and labeled at 
ThermoFischer, [LOCATION_003]. The drug product is provided in vials of 2 40 mg/4.8  mL (50 mg/mL).  
RZL -012 will be dispensed to the sites under monitored conditions by [CONTACT_386349] . 
The active ingredient and formulation manufacturing and packing were in accordance with 
current Good Manufacturing Practices (cGMPs).  
10.[ADDRESS_484209] be accounted for in the study drug 
Dispensing Log, including:  
• Subject number and initials  
• Date study drug was dispensed  
• Quantity dispensed  
• Quantity returned  
• Quantity wasted, as applicable  
All study drug received and dispensed by [CONTACT_386350]. The study drug must be stored in a restricted area with limited access. 
Contents of the study drug containe rs must not be combined.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484210] worsened in severity.  
AEs reported d uring the trial will be graded, documented, and assessed for relationship to study 
drug. Specifically, assessment of AEs related to skin condition  and injection procedure will be 
closely monitored,  including evaluation of edema, pain, bruising, erythema, induration, 
numbness, paresthesia, tenderness, and pruritus . 
Definition of Adverse Events and Adverse Drug Reactions:  
AEs in the eCRF will be classified according to the most recent FDA definitions and in a manner 
consistent with International Conference on Harmonization (ICH) guidelines. As such the 
following definitions will be used:  
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with 
the use of an investiga tional (medicinal) product (IP) or other protocol -imposed intervention, 
regardless of attribution.  An AE may include intercurrent illnesses or injuries that represent an 
exacerbation (increase in frequency, severity, or specificity) of pre -existing condit ions (e.g., 
worsening of asthma).  A laboratory abnormality will be reported on the “Adverse Event” case 
report forms only if it is associated with clinical sequelae or requires therapeutic intervention.  
Whenever possible, it is preferable to record a dia gnosis as the AE term rather than a series of 
symptoms relating to a diagnosis.  AEs will be coded according to the Medical Dictionary for 
Regulatory Activities (MedDRA) and graded according to the  Common Terminology Criteria for 
Adverse Events (CTCAE) v 5.0 (Error! Reference source not found. ). 
The reporting period for AEs starts afte r dosing of study drug and will end at final study visit on  
[ADDRESS_484211] will be followed, at the Investigator’s 
discretion, until resolution of the event or until the subject is deemed “lo st to follow -up”.  AEs 
assessed by [CONTACT_386351] “ongoing” at discharge will be 
monitored by [CONTACT_386352] “lost to follow -up”.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484212] abnormality, with a 
temporal relationship to drug administration which  makes a causal 
relationship improbable, and in which other drugs, chemicals or 
underlying disease provid e plausible  explanations. For the purpose of 
this protocol, the term unlikely will be considered not related to study 
medication and an “Adverse Event”.  
Related  A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the  drug, but which 
could also be explained by [CONTACT_113395]. Information on drug withdrawal may  be lacking or un clear. 
For the purpose of this protocol, an event that has possible or probable 
relationship to study medication will be defined as a “Suspected 
Adverse Drug Reaction”.   
In order to classify AEs and diseases, preferred terms will be assigned by [CONTACT_386353], using MedDRA.  
For those AEs that are not described on the CTCAE v 5.0, such AEs will be graded on a 5 -point 
scale (mild, moderate, severe) and reported as indicated on the CRF. Intensity of such an AE is 
defined as follows:  
Table 5 Severity Assessment Terminology for Reporting Adverse Events (CTCAE v 
5.0) 
CTCAE 
Grade  Common 
Term  Description  
1 Mild  Mild; asymptomatic or mild symptoms; clinical or 
diagnostic observations only; intervention not indicated.  
2 Moderate  Moderate; minimal, local  or noninvasive intervention 
indicated; limiting age -appropriate instrumental Assisted 
Daily Living (ADL).  
3 Severe  Severe or medically significant but not immediately life -
threatening; hospi[INVESTIGATOR_24599]; disabling; limiting self -care 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 63 of 72 CONFIDENTIAL  
 CTCAE 
Grade  Common 
Term  Description  
ADL.  
4 Life-
Threatening  Life-threatening consequences; urgent intervention 
indicated.  
5 Deat h Death related to AE  
11.2 Serious Adverse Events  
According to the ICH Guidelines for Good Clinical Practice (E6), an SAE is any untoward 
medical occurrence during the course of a clinical investigation that is characterized by [CONTACT_113397]:  
• Results in death  
• Is life -threatening  
• Requires in -subject hospi[INVESTIGATOR_1081]  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Important medical events  
Although not an SAE, exposure to study drug during pregnancy, even  if no AE is reported in the 
mother, should be reported within [ADDRESS_484213] report all SAEs promptly to the appropriate IRB/EC as required by 
[CONTACT_113398] 24 hours or 48 hours if on weekend/holiday.  
Report SAEs by [CONTACT_24648]:  
Fax:  +1 -[PHONE_383]  
Email:  Raziel [EMAIL_7467] /[EMAIL_2239]  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484214]  
Medical Monitor  Study Director:  
Patricia Walker , MD, PhD  Racheli Gueta, PhD  
Mobile:  [PHONE_2568]  Mobile:  972-50-7837597  
Email:  [EMAIL_2239]  Email:  racheli@raziel -therapy.com  
11.2.[ADDRESS_484215] be preformed on all women of childbearing potential prior to dosing , and 
all the results of all pregnancy tests are to be recorded in the eCRF’s. All women must have a 
negative pregnancy test to be enrolled into the study. If a pregnancy test turns positive after study 
drug treatment, the patient will be discontinued and protocol -required procedures for study 
discontinuation and follow -up must be preformed. The subject will be followed to determine the 
outcome of the pregnancy.  All women of childbearing potential should be instructed to contact 
[CONTACT_113401] (e.g. missed or late menstrual period) at 
any time during the study.  
The investigator must notify the sponsor  of any pregnancies in accordance with the SAE 
reporting procedures described in section 11.2.[ADDRESS_484216] be recorded on the SAE form provided by [CONTACT_1034]. Additional 
follow -up information (e.g., test results, autopsy, and discharge summary) must be obtained to 
supplement the SAE report form. A copy of all initial and follow -up repo rts must be filed with 
the subject’s eCRF.  
12.[ADDRESS_484217] will be treated with RZL -012 in 
one randomized flank and placebo in the other randomized flan k.  
This will results in comparison of 12 active treated flanks vs. 12 placebo treated flanks.  
12.2 Analysis Data Sets  
Subjects who receive study treatment  will be included in the safety analyses.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 65 of 72 CONFIDENTIAL  
 12.3 Endpoints  Analyses  
All measured variables and derived parameters will be listed individually and, if appropriate, 
tabulated by [CONTACT_9086].  
For categorical variables, summary tables will be provided giving sample size, absolute and 
relative frequency, and 95% confidence interval (CI) for proportion s by [CONTACT_30157].  
For continuous variables, summary tables will be provided giving sample size, arithmetic mean, 
standard deviation, coefficient of variations (CV%), median, minimum and maximum, and 95% 
CI for means of variables by [CONTACT_30157].  
The data will b e analyzed using the SAS version 9.4 (SAS Institute, Cary North Carolina).  
12.4 Safety  
Safety data will be summarized by [CONTACT_113402] (i.e., if a dose reduction occurs,  they will be considered in their init ial group). Descriptive 
statistics will be provided for actual values and change from baseline values for vital signs , blood 
parameters, ECG . 
AE assessment and treatment area evaluation including, but not limited to evaluation of edema, 
pain, bruising, er ythema, induration, numbness, paresthesia, tenderness, and pruritus . 
The incidence and severity of AEs reported during the study and their relationship to study drug 
will be tabulated. AEs will be coded using MedDRA™ and will be presented by [CONTACT_6764]. 
AEs will be graded according to the Common Terminology Criteria for Adverse Events 
(CTCAE) v 5.0 (Error! Reference source not found. ).  
AE data will be listed individually and summarized by [CONTACT_113403] a system organ 
class.  
Skin irritancy AEs related to the injection procedure will be evaluated for frequency, severity 
and duration by [CONTACT_71930].  
Fisher's Exact test will be applied for testing the statistical significance of the difference in 
percent of subjects that experienced Skin irritancy AEs related to the injection procedure 
between the study groups.  
Laboratory tests and ECG res ults will be summarized in appropriate table.  
12.5 Efficacy  
The secondary endpoints will be analyzed as follows:  
• Physician’s GAIS  
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 66 of 72 CONFIDENTIAL  
 • Flank volume reduction from baseline to week 12, assessed by [CONTACT_386354] (GA IS). The proportion of flanks having an improvement as indicated by a score of 0-6 
according to the Physician Global Assessment Scale (GAIS) in RZL -012 vs placebo treated 
flanks will be assessed.  
 
Fisher's Exact test will be applied for testing the statistical significance of the difference in 
percent of subjects for whom an improvement in GAIS was observed between treatment 
groups. Will be calculated along with 95% exact confidence interval by [CONTACT_1570].  
• Correct pre and post -treatment identification  
The p roportion of correctly identified photos ( flank’s treatment ) by [CONTACT_386355] 95% exact confidence interval by [CONTACT_1570].  
• Satisfaction (Yes/No question)  
The proportion of satisfied subjects will be calculated along w ith 95% exact confidence 
intervals for each treatment group.  Fisher's Exact test will be applied for testing the statistical 
significance of the difference in percent of satisfied subjects between treatment groups.  
• Reduction in Volume  
The change and relati ve change from baseline in Flank volume as measured by [CONTACT_386356] [ADDRESS_484218] 
for two means (paired observations) will be applied for testing the statistical significance of 
the change and relative change from baseline at week [ADDRESS_484219] be supported by [CONTACT_24652] (e.g.,  laboratory 
reports, medical records) maintained at the investigational site.  
The Investigator will make all safety assessments (AEs and vital signs) on an ong oing basis. The 
Investigator is required to review all entries on the eCRF and sign at appropriate time intervals.  
13.2 Study Monitoring  
All aspects of the study will be monitored carefully by [CONTACT_1034]’s designees with respect to 
current Good Clinical Practi ce (GCP) and Standard Operating Procedures (SOP) for compliance 
with applicable government regulations. It is the responsibility of the Investigator to provide all 
study records, including eCRFs, source documents, etc., for review and source document 
verif ication by [CONTACT_24653].  
All eCRFs will be 100% source verified against corresponding source documentation (e.g., 
office and clinical laboratory records) for each subject. Clinical monitors will evaluate 
periodically the progress of the study, incl uding the verification of appropriate consent form 
procedures, review of drug accountability and preparation procedures, adherence to dosing 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 67 of 72 CONFIDENTIAL  
 procedures, and the verification of the accuracy and completeness of eCRFs. Clinical monitors 
will also ensure that  all protocol requirements, applicable FDA regulations, other requirements, 
and Investigator’s obligations are being fulfilled.  
13.[ADDRESS_484220] audits at the trial site(s). Audits will include, but are 
not limited to protocol compliance, drug supply, presence of required documents, the informed 
consent process, and comparison of eCRFs with source documents. The investigator agrees to 
participate with audits conducted at a reasonable time in a reasonable mann er. 
Regulatory authorities worldwide may inspect the trial site during or after the trial. The 
investigator should contact [CONTACT_386357] a reasonable time in a reasonable m anner.  
13.[ADDRESS_484221] 
promptly report the deviation to the study monitor.  
The Investigator (or designee) will record any failure to follow  the protocol because of any other 
medical unavoidable reason to avoid the subject's urgent risk and record a document as soon as 
possible stating this and the reason. It must be submitted to the sponsor and the director of the 
study site.  
13.[ADDRESS_484222] notify Raziel  of any change in the 
location, disposition  or custody of the study files. The Investigator  /institution must take 
measures to prevent accidental or premature destruction of essential documents, that is, 
documents that permit evaluation of the conduct of a study and the quality of the data produced , 
including paper copi[INVESTIGATOR_44460] (e.g., subject charts) as well as any original source 
documents that are electronic as required by [CONTACT_25435] . 
All study records must be retained until whichever is the later day in the foll owing : (1) At least 
the date of approval for the drug or (2) the date when [ADDRESS_484223] passed since the 
discontinuation or completion of the study . No records relating to this study should be disposed 
of without the written approval of Raziel . It is the r esponsibility of Raziel  to inform the 
Investigator /institution as to when these documents no longer need to be retained . 
13.[ADDRESS_484224]’s 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. [ADDRESS_484225]’s personal physician or to the appropriate 
medical personnel responsible for the subject’s welfare. Data generated as a result of this study 
are to be available fo r inspection on request by [CONTACT_230333], the Sponsor clinical monitor (or designee), and the IRB/EC.  
All laboratory specimens, evaluation forms, reports, and other records that leave the site will be 
identified by a co ded number to maintain subject confidentiality. All records will be kept in a 
locked and secured area. All computer entry and networking programs will be identifiable only 
by [CONTACT_24655]. Clinical information will not be released without written permissi on from the 
subject, except as necessary for monitoring by [CONTACT_1201], the FDA, or the study Sponsor.  
Any information, inventions, or discoveries (whether patentable or not), innovations, 
suggestions, ideas, and reports, made or developed by [CONTACT_737]( s) as a result of 
conducting this study shall be promptly disclosed to the Sponsor and shall be the sole property of 
the Sponsor. The Investigator agrees, upon the Sponsor’s request and at the Sponsor's expense, to 
execute such documents and to take such o ther actions, as the Sponsor deems necessary or 
appropriate, to obtain patents in the Sponsor’s name [CONTACT_24668].  
The results of this study will be published under the direction of the Sponsor. Results will not be 
published without prior review and approval by [CONTACT_113405].  
14.0 PROTECTION OF HUMAN SUBJECTS  
14.1 Basic Principles  
The study will be conducted in accordance with the relevant regulatory requirements, this 
protocol, and ethical principles that are consisted with the GCP guideline developed by [CONTACT_386358] (ICH ). This clinical trial will also be conducted in compliance 
with Declaration of Helsinki, protocol, Sta ndard specified in the relevant local regulations . Prior 
to initiation of the study, the investigator and the sponsor should obtain approval from the 
IRB/IEC on this protocol and any further amendments, and the subject information and informed 
consent form . 
Any suspected serious breaches must be immediately reported to the sponsor. A serious breach is 
a breach of the conditions and principles of GCP in connection with the study or the protocol, 
which is likely to affect, to a significant degree, the safety of the subjects or the scientific value 
of the study.  
Personnel involved in the study will be qualified by [CONTACT_8640], training, and experience to 
perform their respective tasks.  
14.[ADDRESS_484226]/Ethics Committee  
The Investigator or designee agree s to provide the IRB/EC with all appropriate material, 
including a copy of the ICF. The study will not be initiated until the Investigator obtains written 
approval of the research plan and the ICF from the appropriate IRB/EC and copi[INVESTIGATOR_386309], Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 69 of 72 CONFIDENTIAL  
 documents a re received by [CONTACT_1034]. Appropriate reports on the progress of this study will be 
made by [CONTACT_26492]/EC and Sponsor in accordance with applicable government 
regulations and in agreement with the policies established by [CONTACT_1034]. The  Sponsor ensures 
that the IRB/EC complies with the requirements set forth in 21  CFR Part 56  (Code of Federal 
Regulations) . 
14.3 Informed Consent  
The investigator is responsible for:  
• Explain the subject of the study, the risks and benefits expected from partic ipating in the study, 
and that the participation is voluntary so that the subject can understand.  
• Obtain informed consent to participate in the trial from the subject by [CONTACT_386359].  
• Properly answer questions from subjects at any time during the trial and if new information that 
can affect the subject's intention to continue the trial is obtained while the subject is participating 
in the trial, the information is promptly communicated to the subject.  
• Give a copy of the written consent form to the study participants and keep one copy at the 
study site.  
14.[ADDRESS_484227] participating the clinical trial due to the willful or gross negligence 
of investigator’s site, indemnification will be discussed based on the contract with the site. The 
indemnification for the health damage and the payment to subjects will be described in the ICF.  
14.5 Completion of the Study  
If the clinical trial is c ompleted at the study site,  the investigator will notify the director of the 
study site that the trial has been completed and provide an approximate summary in writing.  The 
director of the study site will promptly notify the IRB/EC and the Sponsor in writ ing about the 
completion.  
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version: 1. 1 
 
30 May 2022  Page 70 of 72 CONFIDENTIAL  
  
Appendix A:  Schedule of Study Procedures  
Raziel Therapeutics Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version:1.0  
22 November   2021                                                    71 of 72                                                 CONFIDENTIAL                                                                                                        Table 1: Schedule of Study Procedures  
Study 
Procedure  Screenin
g Day   
Double Blind Phase  Open Label Phase  
Study Day  Day -
28 
throug
h Day 
-1 Baseli
ne 
Day 0 
a Da
y 1 
e Wee
k 
1(±2 
day
s) Wee
k 4 
(±5 
day
s) Wee
k 8 
(±5 
days
) Wee
k 12 
(±5 
day
s) Da
y 0 
a Wee
k 
1(±2 
day
s) Wee
k 4 
(±5 
day
s) Wee
k 8 
(±5 
day
s) Wee
k 12 
(±5 
days
)/ 
Fina
l 
visit 
Signed 
informed 
consent  X   
         
Eligibility 
criteria  X Prec 
X           
Medical 
history  X            
Physical 
Exam  X      X     X 
Concomitant 
Medication  X X  X X X X X X X X X 
Pregnancy ß -
hCG  X            
Weight 
measurement
s X X  
 X X X   X X X 
Pharmacokin
etics blood 
samples   X X 
         
Hematology 
and 
Chemistryb X   
X X  X  X X  X 
ECG  X   X X  X  X X  X 
Vital signs  X Prec 
X 
postc  
X X X X Pre
c X 
pos
tc X X X X 
Injection of 
RZL -012 or 
placebo   X  
    X     
Physician’s 
GAIS      X X X   X X X 
Subject 
Satisfaction 
questionnaire     
 X X X   X X X 
Raziel Therapeutics Ltd.  Protocol RZL -012-FL-P2US -001 
RZL -012 Version:1.0  
22 November   2021                                                    72 of 72                                                 CONFIDENTIAL                                                                                                        a. Day 0 defined as the day of RZL -012 or placebo  injection.  
b. In case of clinically significant values  at any visit, an unscheduled visit  will be added  
c. Pre/post – refers to before/after injection, respectively  
d. AEs will be recorded throughout the study until the final study visit.  In case of ongoing AEs at the final study visit an 
unscheduled visit will be  scheduled for further follow -up.  Treatment area will be evaluat ed includ ing, but is not limited 
to, evaluation of edema, pain, bruising, erythema, induration, numbness, paresthesia, tenderness, and pruritus.  
e. Day 1 visit is only for subjects who volunteer  for PK blood samples  
 
 
 Study 
Procedure  Screenin
g Day   
Double Blind Phase  Open Label Phase  
Study Day  Day -
28 
throug
h Day 
-1 Baseli
ne 
Day 0 
a Da
y 1 
e Wee
k 
1(±2 
day
s) Wee
k 4 
(±5 
day
s) Wee
k 8 
(±5 
days
) Wee
k 12 
(±5 
day
s) Da
y 0 
a Wee
k 
1(±2 
day
s) Wee
k 4 
(±5 
day
s) Wee
k 8 
(±5 
day
s) Wee
k 12 
(±5 
days
)/ 
Fina
l 
visit 
2D 
Standardized 
photography  X   
X X X X X X X X X 
3D 
photography  X   X X X X X X X X X 
AEsd   X X X X X X X X X X 